category,medicine_name,therapeutic_area,common_name,active_substance,product_number,patient_safety,authorisation_status,atc_code,additional_monitoring,generic,biosimilar,conditional_approval,exceptional_circumstances,accelerated_assessment,orphan_medicine,marketing_authorisation_date,date_of_refusal_of_marketing_authorisation,marketing_authorisation_holder_company_name,pharmacotherapeutic_group,date_of_opinion,decision_date,revision_number,condition_indication,species,first_published,revision_date,url
human,Vimpat,Epilepsy,lacosamide,lacosamide,863,False,authorised,N03AX18,False,False,False,False,False,False,False,8/29/08,,UCB Pharma SA,"Antiepileptics,",6/26/08,10/12/22,44.0,"Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.",,2018-07-26T12:09:00Z,2023-03-08T18:25:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat
human,Briviact (in Italy: Nubriveo),Epilepsy,brivaracetam,brivaracetam,3898,False,authorised,N03AX23,False,False,False,False,False,False,False,1/13/16,,UCB Pharma SA,"Antiepileptics,",,2/24/22,19.0,Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.,,2018-07-11T12:01:00Z,2023-03-08T18:12:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo
human,Tecvayli,Multiple Myeloma,teclistamab,teclistamab,5865,False,authorised,L01F,True,False,False,True,False,False,False,8/23/22,,Janssen-Cilag International N.V.,Antineoplastic agents,7/21/22,,,"TECVAYLI is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.",,2022-07-18T14:04:00Z,2023-03-07T16:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli
human,Tivicay,HIV Infections,dolutegravir,dolutegravir,2753,False,authorised,J05AX12,False,False,False,False,False,False,False,1/16/14,,ViiV Healthcare BV,Antivirals for systemic use,11/21/13,3/6/23,33.0,"Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.",,2018-03-01T01:00:00Z,2023-03-07T12:33:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay
human,Empliciti,Multiple Myeloma,elotuzumab,elotuzumab,3967,False,authorised,L01FX08,False,False,False,False,False,True,False,5/11/16,,Bristol-Myers Squibb Pharma EEIG,Antineoplastic agents,1/28/16,3/3/23,11.0,Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).,,2017-07-13T17:37:00Z,2023-03-06T13:06:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/empliciti
human,Ebymect,"Diabetes Mellitus, Type 2","dapagliflozin, metformin","dapagliflozin propanediol monohydrate, metformin hydrochloride",4162,False,authorised,A10BD15,False,False,False,False,False,False,False,11/15/15,,AstraZeneca AB,Drugs used in diabetes,9/23/15,2/6/23,18.0,"Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.",,2017-12-20T18:04:00Z,2023-03-06T12:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect
human,Xigduo,"Diabetes Mellitus, Type 2","dapagliflozin, metformin","metformin hydrochloride, dapagliflozin propanediol monohydrate",2672,False,authorised,A10BD15,False,False,False,False,False,False,False,1/16/14,,AstraZeneca AB,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",11/20/13,2/3/23,19.0,"Xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:•    in patients insufficiently controlled on their maximally tolerated dose of metformin alone •    in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products•    in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",,2017-12-20T13:09:00Z,2023-03-06T11:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xigduo
human,Prezista,HIV Infections,darunavir,darunavir,707,False,authorised,J05AE10,False,False,False,False,False,False,False,2/11/07,,Janssen-Cilag International NV,Antivirals for systemic use,12/14/06,11/10/22,54.0,"PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight.PREZISTA, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).In deciding to initiate treatment with PREZISTA co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV 1) infection.PREZISTA 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:For the treatment of HIV 1 infection in antiretroviral treatment (ART) experienced adult patients, including those that have been highly pre treated.For the treatment of HIV 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with PREZISTA co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.PREZISTA, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV 1) infection.PREZISTA, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).PREZISTA 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART) naïve.ART experienced with no darunavir resistance associated mutations (DRV RAMs) and who have plasma HIV 1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/L. In deciding to initiate treatment with PREZISTA in such ART experienced patients, genotypic testing should guide the use of PREZISTA.",,2018-07-06T00:00:00Z,2023-03-03T15:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/prezista
human,Efavirenz Teva,HIV Infections,efavirenz,efavirenz,2352,False,authorised,J05AG03,False,True,False,False,False,False,False,1/9/12,,Teva B.V.,Antivirals for systemic use,,2/27/23,12.0,"Efavirenz is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children 3 years of age and older.Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with protease inhibitors (PIs) has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing efavirenz.",,2016-09-09T11:59:00Z,2023-03-03T13:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-teva
human,Maviret,"Hepatitis C, Chronic","glecaprevir, pibrentasvir","glecaprevir, pibrentasvir",4430,False,authorised,J05AP57,False,False,False,False,False,True,False,7/26/17,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,6/22/17,3/2/23,21.0,Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.,,2018-06-15T12:11:00Z,2023-03-02T14:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/maviret
human,Invokana,"Diabetes Mellitus, Type 2",canagliflozin,canagliflozin,2649,False,authorised,A10BK02,False,False,False,False,False,False,False,11/15/13,,Janssen-Cilag International NV,Drugs used in diabetes,9/19/13,2/24/23,21.0,"Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.",,2018-07-26T12:08:00Z,2023-02-27T16:19:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/invokana
human,Vokanamet,"Diabetes Mellitus, Type 2","canagliflozin, metformin","canagliflozin, metformin hydrochloride",2656,False,authorised,A10BD16,False,False,False,False,False,False,False,4/23/14,,Janssen-Cilag International NV,Drugs used in diabetes,,2/24/23,20.0,"Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated doses of metformin alonein patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control.in patients already being treated with the combination of canagliflozin and metformin as separate tabletsFor study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",,2018-03-15T17:03:00Z,2023-02-27T15:44:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet
human,Ulunar Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide","glycopyrronium bromide, indacaterol maleate",3875,False,authorised,R03AL04,False,False,False,False,False,False,False,4/23/14,,Novartis Europharm Limited,"Drugs for obstructive airway diseases,",,11/15/21,14.0,Ulunar Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-05-08T12:05:00Z,2023-02-24T11:19:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ulunar-breezhaler
human,Telmisartan Actavis,Hypertension,telmisartan,telmisartan,1168,False,authorised,C09CA07,False,True,False,False,False,False,False,9/29/10,,Actavis Group PTC ehf,Agents acting on the renin-angiotensin system,6/24/10,9/24/21,11.0,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.",,2018-08-21T00:00:00Z,2023-02-24T11:08:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis
human,Mounjaro,"Diabetes Mellitus, Type 2",tirzepatide,tirzepatide,5620,False,authorised,A10B,False,False,False,False,False,False,False,9/15/22,,Eli Lilly Nederland B.V.,Drugs used in diabetes,7/21/22,2/23/23,1.0,"Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.",,2022-07-18T13:49:00Z,2023-02-23T16:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
human,Rasilez,Hypertension,aliskiren,aliskiren,780,False,authorised,C09XA02,False,False,False,False,False,False,False,8/22/07,,Noden Pharma DAC,Agents acting on the renin-angiotensin system,,2/23/23,27.0,Treatment of essential hypertension.,,2018-05-04T00:00:00Z,2023-02-23T16:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez
human,Rasagiline Mylan,Parkinson Disease,rasagiline,rasagiline tartrate,4064,False,authorised,N04BD02,False,True,False,False,False,False,False,4/4/16,,Mylan Pharmaceuticals Limited,Anti-Parkinson drugs,1/28/16,2/22/23,7.0,Rasagiline Mylan is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.,,2016-05-18T12:02:00Z,2023-02-23T11:58:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-mylan
human,Stalevo,Parkinson Disease,"levodopa, carbidopa, entacapone","levodopa, carbidopa, entacapone",511,False,authorised,N04BA03,False,False,False,False,False,False,False,10/17/03,,Orion Corporation,Anti-Parkinson drugs,,1/12/23,29.0,Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,,2018-02-08T01:00:00Z,2023-02-23T10:07:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo
human,Buccolam,Epilepsy,midazolam,midazolam,2267,False,authorised,N05CD08,False,False,False,False,False,False,False,9/4/11,,Laboratorios Lesvi S.L.,"Psycholeptics,",6/23/11,2/8/23,17.0,"Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.",,2018-07-25T12:52:00Z,2023-02-22T17:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam
human,Inovelon,Epilepsy,rufinamide,rufinamide,660,False,authorised,N03AF03,False,False,False,False,False,False,False,1/16/07,,Eisai GmbH,"Antiepileptics,",,2/16/23,23.0,Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.,,2018-08-03T09:57:00Z,2023-02-22T16:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon
human,Stocrin,HIV Infections,efavirenz,efavirenz,250,False,authorised,J05AG03,False,False,False,False,False,False,False,5/28/99,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,2/24/99,2/20/23,48.0,"Stocrin is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Stocrin has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Stocrin.",,2018-07-30T00:00:00Z,2023-02-22T11:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/stocrin
human,Tolura,Hypertension,telmisartan,telmisartan,1196,False,authorised,C09CA07,False,True,False,False,False,False,False,6/4/10,,"Krka, d.d., Novo mesto ","Angiotensin II antagonists, plain",3/18/10,1/26/23,11.0,HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.,,2018-02-19T22:29:00Z,2023-02-22T10:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tolura
human,Pifeltro,HIV Infections,doravirine,doravirine,4747,False,authorised,J05AG06,True,False,False,False,False,False,False,11/22/18,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,9/20/18,10/10/22,7.0,"Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class.",,2018-09-21T14:01:00Z,2023-02-20T18:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro
human,Delstrigo,HIV Infections,"doravirine, lamivudine, tenofovir disoproxil","doravirine, lamivudine, tenofovir disoproxil fumarate",4746,False,authorised,J05AR,True,False,False,False,False,False,False,11/22/18,,Merck Sharp & Dohme B.V.,"Antivirals for treatment of HIV infections, combinations",9/20/18,10/10/22,10.0,"Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir., , Delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.,",,2018-09-21T14:01:00Z,2023-02-20T17:58:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/delstrigo
human,Nexpovio,Multiple Myeloma,selinexor,selinexor,5127,False,authorised,L01XX66,True,False,False,False,False,False,False,3/26/21,,Stemline Therapeutics B.V.,Antineoplastic agents,1/28/21,1/26/23,7.0,"NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.",,2021-05-27T14:50:00Z,2023-02-20T15:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio
human,Odefsey,HIV Infections,"emtricitabine, rilpivirine, tenofovir alafenamide","emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide",4156,False,authorised,J05AR19,False,False,False,False,False,False,False,6/21/16,,Gilead Sciences Ireland UC,Antivirals for systemic use,4/28/16,2/16/23,20.0,"Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL.,",,2018-05-16T16:45:00Z,2023-02-20T12:17:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey
human,Velmetia,"Diabetes Mellitus, Type 2","sitagliptin, metformin","sitagliptin, metformin hydrochloride",862,False,authorised,A10BD07,False,False,False,False,False,False,False,7/16/08,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,4/24/08,1/30/23,35.0,"For patients with type-2 diabetes mellitus:, , , 	Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin., 	Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea., 	Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist., 	Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control., ,",,2018-06-29T02:00:00Z,2023-02-20T10:46:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/velmetia
human,Descovy,HIV Infections,"emtricitabine, tenofovir alafenamide","emtricitabine, tenofovir alafenamide",4094,False,authorised,J05AR17,False,False,False,False,False,False,False,4/21/16,,Gilead Sciences Ireland UC,Antivirals for systemic use,2/25/16,2/16/23,20.0,Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).,,2018-05-28T11:44:00Z,2023-02-17T12:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/descovy
human,Amglidia,Diabetes Mellitus,glibenclamide,glibenclamide,4379,False,authorised,A10BB01,False,False,False,False,False,False,True,5/24/18,,Ammtek,Drugs used in diabetes,12/14/17,2/9/23,5.0,"Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.",,2018-07-31T12:02:00Z,2023-02-16T16:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia
human,CoAprovel,Hypertension,"irbesartan, hydrochlorothiazide","irbesartan, hydrochlorothiazide",222,False,authorised,C09DA04,False,False,False,False,False,False,False,10/14/98,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,7/22/98,1/30/23,46.0,Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,,2017-08-22T00:09:00Z,2023-02-16T14:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/coaprovel
human,Aprovel,Hypertension,irbesartan,irbesartan,141,False,authorised,C09CA04,False,False,False,False,False,False,False,8/26/97,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,1/30/23,47.0,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.,,2017-08-02T00:00:00Z,2023-02-16T14:44:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/aprovel
human,Darunavir Krka,HIV Infections,darunavir,darunavir,4273,False,authorised,J05AE10,False,True,False,False,False,False,False,1/26/18,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,11/9/17,2/9/23,9.0,"400 and 800 mg, , Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection., , Darunavir Krka 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:, , , 	antiretroviral therapy (ART)-naïve (see section 4.2)., 	ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1)., , , 600 mg , , Darunavir Krka, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection., , Darunavir Krka 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):, , , 	For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated., 	For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight., , , In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir.,",,2018-06-13T12:12:00Z,2023-02-16T11:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-krka
human,Tybost,HIV Infections,cobicistat,cobicistat,2572,False,authorised,V03AX03,False,False,False,False,False,False,False,9/19/13,,Gilead Sciences Ireland UC,Antivirals for systemic use,,2/13/23,15.0,Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.,,2018-07-26T11:29:00Z,2023-02-14T12:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tybost
human,Epclusa,"Hepatitis C, Chronic","sofosbuvir, velpatasvir","sofosbuvir, velpatasvir",4210,False,authorised,J05A,False,False,False,False,False,True,False,7/6/16,,Gilead Sciences Ireland UC,Antivirals for systemic use,5/26/16,1/12/23,19.0,"Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).",,2018-06-14T09:55:00Z,2023-02-09T11:47:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa
human,Harvoni,"Hepatitis C, Chronic","ledispavir, sofosbuvir","ledipasvir, sofosbuvir",3850,False,authorised,J05AX65,False,False,False,False,False,True,False,11/17/14,,Gilead Sciences Ireland UC,Antivirals for systemic use,,1/12/23,27.0,"Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.",,2018-06-07T09:51:00Z,2023-02-09T11:37:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni
human,Sovaldi,"Hepatitis C, Chronic",sofosbuvir,sofosbuvir,2798,False,authorised,J05AX15,False,False,False,False,False,True,False,1/16/14,,Gilead Sciences Ireland UC,Antivirals for systemic use,11/21/13,1/12/23,27.0,"Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.",,2018-08-06T13:53:00Z,2023-02-09T11:29:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi
human,Vosevi,"Hepatitis C, Chronic","sofosbuvir, velpatasvir, voxilaprevi","sofosbuvir, velpatasvir, voxilaprevi",4350,False,authorised,J05A,False,False,False,False,False,False,False,7/26/17,,Gilead Sciences Ireland UC,Antivirals for systemic use,6/22/17,1/12/23,14.0,"Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).,",,2018-06-14T12:11:00Z,2023-02-09T10:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi
human,Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"emtricitabine, tenofovir disoproxil","emtricitabine, tenofovir disoproxil maleate",4050,False,authorised,J05AR03,False,True,False,False,False,False,False,12/16/16,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,10/13/16,2/2/23,12.0,"Treatment of HIV-1 infection:, , , 	Emtricitabine/Tenofovir disoproxil Mylan is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1)., 	Emtricitabine/Tenofovir disoproxil Mylan is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1)., , , Pre-exposure prophylaxis (PrEP):, , , 	Emtricitabine/Tenofovir disoproxil Mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1)., ,",,2017-06-02T12:00:00Z,2023-02-06T14:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-mylan
human,Darunavir Krka d.d.,HIV Infections,darunavir,darunavir,4891,False,withdrawn,J05AE10,False,True,False,False,False,False,False,1/18/18,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,,1/22/23,8.0,"400mg and 800 mg Film-coated TabletsDarunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka d.d., co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection in adult patients (see section 4.2).Darunavir Krka d.d. 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (ART)-naïve (see section 4.2).ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).600mg Film-coated TabletsDarunavir Krka d.d., co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.Darunavir Krka d.d. 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir.",,2018-06-13T12:12:00Z,2023-02-03T13:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-krka-dd
human,Truvada,HIV Infections,"emtricitabine, tenofovir disoproxil","emtricitabine, tenofovir disoproxil fumarate",594,False,authorised,J05AR03,False,False,False,False,False,False,False,2/20/05,,Gilead Sciences Ireland UC,Antivirals for systemic use,11/18/04,1/12/23,46.0,"Treatment of HIV-1 infection:, , , 	Truvada is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults., 	Truvada is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years., , , Pre-exposure prophylaxis (PrEP):, , , 	Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk., ,",,2017-07-19T00:00:00Z,2023-02-02T16:18:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/truvada
human,Stribild,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil","elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",2574,False,authorised,J05AR09,False,False,False,False,False,False,False,5/24/13,,Gilead Sciences Ireland UC,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,1/12/23,25.0,Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.,,2018-07-19T16:41:00Z,2023-02-02T15:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
human,Karvezide,Hypertension,"irbesartan, hydrochlorothiazide","irbesartan, hydrochlorothiazide",221,False,authorised,C09DA04,False,False,False,False,False,False,False,10/16/98,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,12/12/22,44.0,"Treatment of essential hypertension., , This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,",,2017-08-24T00:00:00Z,2023-02-02T14:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/karvezide
human,Segluromet,"Diabetes Mellitus, Type 2","ertugliflozin, metformin hydrochloride","ertugliflozin l-pyroglutamic acid, metformin hydrochloride",4314,False,authorised,A10BD23,False,False,False,False,False,False,False,3/23/18,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",1/25/18,11/9/22,6.0,"Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:, , , 	in patients not adequately controlled on their maximally tolerated dose of metformin alone, 	in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes, 	in patients already being treated with the combination of ertugliflozin and metformin as separate tablets., ,",,2018-04-26T12:07:00Z,2023-02-02T14:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/segluromet
human,Lyxumia,"Diabetes Mellitus, Type 2",lixisenatide,lixisenatide,2445,False,authorised,A10BJ03,False,False,False,False,False,False,False,1/31/13,,Sanofi Winthrop Industrie,"Glucagon-like peptide-1 (GLP-1) analogues, Drugs used in diabetes",11/15/12,1/10/23,17.0,"Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.",,2017-09-18T00:00:00Z,2023-02-02T14:19:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia
human,Karvea,Hypertension,irbesartan,irbesartan,142,False,authorised,C09CA04,False,False,False,False,False,False,False,8/26/97,,Sanofi Winthrop Industrie,Agents acting on the renin-angiotensin system,,12/16/22,45.0,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,,2017-08-02T00:00:00Z,2023-02-02T13:07:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/karvea
human,Relvar Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, vilanterol","fluticasone furoate, vilanterol",2673,False,authorised,R03AK10,False,False,False,False,False,False,False,11/13/13,,GlaxoSmithKline (Ireland) Limited,Adrenergics and other drugs for obstructive airway diseases,9/19/13,9/15/22,24.0,"Asthma indication:, , Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:, , , 	patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists., 	patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist., , , COPD indication:, , Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1",,2018-07-26T12:08:00Z,2023-02-02T13:04:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta
human,Juluca,HIV Infections,"dolutegravir, rilpivirine","dolutegravir sodium, rilpivirine hydrochloride",4427,False,authorised,J05AR,False,False,False,False,False,False,False,5/16/18,,ViiV Healthcare B.V.,Antivirals for systemic use,3/22/18,1/12/23,14.0,Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA,,2018-05-16T12:26:00Z,2023-02-02T12:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/juluca
human,Tesavel,"Diabetes Mellitus, Type 2",sitagliptin,sitagliptin,910,False,authorised,A10BH01,False,False,False,False,False,False,False,1/10/08,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,11/15/07,1/30/23,27.0,"For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.",,2018-08-08T00:00:00Z,2023-02-02T12:12:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tesavel
human,Ninlaro,Multiple Myeloma,ixazomib,ixazomib citrate,3844,False,authorised,L01XG03,True,False,False,True,False,False,True,11/21/16,,Takeda Pharma A/S,Antineoplastic agents,9/15/16,1/12/23,15.0,Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.,,2018-09-17T13:45:00Z,2023-02-01T13:21:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro
human,Ogluo,Diabetes Mellitus,glucagon,glucagon,5391,False,authorised,H04AA01,False,False,False,False,False,False,False,2/11/21,,Tetris Pharma B.V,"Pancreatic hormones, Glycogenolytic hormones",12/10/20,2/1/23,4.0,"Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.",,2021-02-26T18:00:00Z,2023-02-01T13:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo
human,Efficib,"Diabetes Mellitus, Type 2","sitagliptin, metformin","sitagliptin, metformin hydrochloride",896,False,authorised,A10BD07,False,False,False,False,False,False,False,7/15/08,,Merck Sharp and Dohme B.V,Drugs used in diabetes,4/24/08,1/31/23,32.0,"For patients with type-2 diabetes mellitus:Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Efficib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.",,2018-05-22T00:00:00Z,2023-01-31T14:09:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/efficib
human,Xelevia,"Diabetes Mellitus, Type 2",sitagliptin,sitagliptin,762,False,authorised,A10BH01,False,False,False,False,False,False,False,3/21/07,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,1/24/07,1/30/23,37.0,"For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",,2018-08-20T00:00:00Z,2023-01-31T13:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xelevia
human,Liprolog,Diabetes Mellitus,insulin lispro,insulin lispro,393,False,authorised,"A10AB04, A10AD04",False,False,False,False,False,False,False,8/1/01,,Eli Lilly Nederland B.V.,Drugs used in diabetes,4/26/01,1/26/23,30.0,For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilisation of diabetes mellitus.,,2017-10-23T00:00:00Z,2023-01-30T12:31:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/liprolog-0
human,Rybrevant,"Carcinoma, Non-Small-Cell Lung",amivantamab,amivantamab,5454,False,authorised,L01XC,True,False,False,True,False,False,False,12/9/21,,Janssen-Cilag International N.V.   ,Antineoplastic agents,10/14/21,11/29/22,2.0,"Rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy.",,2021-10-12T10:06:00Z,2023-01-30T10:13:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
human,Tabrecta,"Carcinoma, Non-Small-Cell Lung",capmatinib,capmatinib dihydrochloride monohydrate,4845,False,authorised,L01EX17,True,False,False,False,False,False,False,6/20/22,,Novartis Europharm Limited ,Antineoplastic agents,4/22/22,12/1/22,1.0,"Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.",,2022-04-13T17:44:00Z,2023-01-25T13:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta
human,Alecensa,"Carcinoma, Non-Small-Cell Lung",alectinib,alectinib hydrochloride,4164,False,authorised,L01ED03,True,False,False,False,False,False,False,2/16/17,,Roche Registration GmbH,Antineoplastic agents,12/15/16,8/2/22,13.0,"Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)., , Alecensa as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC previously treated with crizotinib.,",,2018-08-09T15:09:00Z,2023-01-23T16:57:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa
human,Neofordex,Multiple Myeloma,dexamethasone,dexamethasone,4071,False,authorised,H02AB02,False,False,False,False,False,False,False,3/16/16,,Laboratoires CTRS ,Corticosteroids for systemic use,12/17/15,1/18/23,10.0,Treatment of multiple myeloma.,,2018-05-28T11:58:00Z,2023-01-23T11:09:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/neofordex-0
human,Biktarvy,HIV Infections,"bictegravir, emtricitabine, tenofovir alafenamide","bictegravir, emtricitabine, tenofovir alafenamide, fumarate",4449,False,authorised,J05AR20,False,False,False,False,False,False,False,6/21/18,,Gilead Sciences Ireland UC,Antivirals for systemic use,4/26/18,1/10/23,15.0,"Biktarvy is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.(see section 5.1),",,2018-06-21T12:10:00Z,2023-01-23T10:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy
human,Sarclisa,Multiple Myeloma,isatuximab,isatuximab,4977,False,authorised,L01XC38,True,False,False,False,False,False,False,5/30/20,,Sanofi Winthrop Industrie,Antineoplastic agents,3/26/20,12/20/22,6.0,"Sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).",,2020-06-12T16:00:00Z,2023-01-18T15:33:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa
human,Oprymea,Parkinson Disease,pramipexole,pramipexole dihydrochloride monohydrate,941,False,authorised,N04BC05,False,True,False,False,False,False,False,9/12/08,,"Krka, d.d., Novo mesto",Anti-Parkinson drugs,,1/10/23,22.0,"Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).",,2018-03-12T11:27:00Z,2023-01-17T15:02:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/oprymea
human,Carvykti,Multiple Myeloma,ciltacabtagene autoleucel,ciltacabtagene autoleucel,5095,False,authorised,,True,False,False,True,False,False,True,5/25/22,,Janssen-Cilag International NV,,3/24/22,12/15/22,1.0,"Carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.",,2022-03-25T16:15:00Z,2023-01-17T11:40:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti
human,Levodopa/Carbidopa/Entacapone Orion,Parkinson Disease,"levodopa, carbidopa, entacapone","levodopa, carbidopa, entacapone",2441,False,authorised,N04BA03,False,False,False,False,False,False,False,8/23/11,,Orion Corporation,Nervous system,,1/12/23,13.0,Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment.,,2018-02-08T13:52:00Z,2023-01-16T16:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levodopa-carbidopa-entacapone-orion
human,Trogarzo,HIV Infections,ibalizumab,ibalizumab,4961,False,withdrawn,J05AX,True,False,False,False,False,False,False,9/26/19,,Theratechnologies Europe Limited,Antivirals for systemic use,7/25/19,10/12/22,7.0,"Trogarzo, in combination with other antiretroviral(s), is indicated for the treatment of adults infected with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen.",,2019-10-10T10:47:00Z,2023-01-16T12:55:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trogarzo
human,Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz),Parkinson Disease,"levodopa, carbidopa, entacapone","levodopa, carbidopa, entacapone",2785,False,authorised,N04BA03,False,False,False,False,False,False,False,11/11/13,,Orion Corporation,Anti-Parkinson drugs,9/19/13,1/12/23,10.0,Corbilta is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.,,2018-07-06T12:06:00Z,2023-01-16T12:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/corbilta
human,Vocabria,HIV Infections,cabotegravir,"cabotegavir sodium, cabotegravir",4976,False,authorised,J05AX,True,False,False,False,False,False,False,12/17/20,,ViiV Healthcare B.V.,Antivirals for systemic use,10/15/20,1/10/23,8.0,Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA,,2021-01-05T15:20:00Z,2023-01-12T17:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vocabria
human,Duaklir Genuair,"Pulmonary Disease, Chronic Obstructive","aclidinium bromide, formoterol","aclidinium bromide, formoterol fumarate dihydrate",3745,False,authorised,R03AL,True,False,False,False,False,False,False,11/19/14,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases,",9/25/14,1/9/23,15.0,Duaklir Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-05-18T12:04:00Z,2023-01-11T18:45:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/duaklir-genuair
human,Eklira Genuair,"Pulmonary Disease, Chronic Obstructive",aclidinium bromide,aclidinium bromide,2211,False,authorised,R03BB,True,False,False,False,False,False,False,7/20/12,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases,",,1/9/23,20.0,Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-05-18T13:53:00Z,2023-01-11T18:06:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair
human,Bretaris Genuair,"Pulmonary Disease, Chronic Obstructive",aclidinium bromide,aclidinium bromide,2706,False,authorised,R03BB,True,False,False,False,False,False,False,7/20/12,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases,",,12/16/22,18.0,Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-05-18T16:26:00Z,2023-01-05T10:13:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bretaris-genuair
human,Brimica Genuair,"Pulmonary Disease, Chronic Obstructive","aclidinium, formoterol fumarate dihydrate","formoterol fumarate dihydrate, aclidinium bromide",3969,False,authorised,R03AL05,True,False,False,False,False,False,False,11/19/14,,Covis Pharma Europe B.V.,"Drugs for obstructive airway diseases,",,12/16/22,13.0,Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-05-18T12:04:00Z,2023-01-04T18:46:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair
human,Vipidia,"Diabetes Mellitus, Type 2",alogliptin benzoate,alogliptin,2182,False,authorised,A10BH04,False,False,False,False,False,False,False,9/18/13,,Takeda Pharma A/S,"Drugs used in diabetes, Dipeptidyl peptidase 4 (DPP-4) inhibitors",,9/7/22,9.0,"Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",,2015-01-15T13:32:00Z,2022-12-22T12:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia
human,Exforge HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide","valsartan, hydrochlorothiazide, amlodipine besilate",1068,False,authorised,C09DX01,False,False,False,False,False,False,False,10/15/09,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,12/15/22,23.0,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",,2018-06-07T00:00:00Z,2022-12-21T14:16:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct
human,Dafiro HCT,Hypertension,"amlodipine besilate, valsartan, hydrochlorothiazide","valsartan, hydrochlorothiazide, amlodipine besilate",1160,False,authorised,C09DX01,False,False,False,False,False,False,False,11/3/09,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,12/15/22,25.0,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",,2018-06-25T00:00:00Z,2022-12-20T16:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro-hct
human,Copalia HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide","amlodipine, valsartan, hydrochlorothiazide",1159,False,authorised,C09DX01,False,False,False,False,False,False,False,11/3/09,,Novartis Europharm Limited,"Angiotensin II antagonists and calcium channel blockers, Angiotensin II antagonists, combinations, Agents acting on the renin-angiotensin system",,12/15/22,23.0,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",,2018-04-17T00:00:00Z,2022-12-20T16:47:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct
human,Pepaxti,Multiple Myeloma,melphalan flufenamide,melphalan flufenamide hydrochloride,5681,False,authorised,L01AA10,False,False,False,False,False,False,False,8/17/22,,Oncopeptides AB,Antineoplastic agents,,12/19/22,1.0,"Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4).",,2022-06-21T16:28:00Z,2022-12-19T16:58:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pepaxti
human,Steglujan,"Diabetes Mellitus, Type 2","ertugliflozin, sitagliptin","ertugliflozin l-pyroglutamic acid, sitagliptin phosphate monohydrate",4313,False,authorised,A10BD24,False,False,False,False,False,False,False,3/23/18,,Merck Sharp & Dohme B.V.,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,12/15/22,9.0,Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.,,2018-08-23T12:07:00Z,2022-12-15T18:45:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/steglujan
human,Komboglyze,"Diabetes Mellitus, Type 2","saxagliptin, metformin hydrochloride","metformin hydrochloride, saxagliptin hydrochloride",2059,False,authorised,A10BD10,False,False,False,False,False,False,False,11/24/11,,AstraZeneca AB ,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,12/6/22,19.0,Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.,,2017-06-26T00:00:00Z,2022-12-15T17:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/komboglyze
human,Onglyza,"Diabetes Mellitus, Type 2",saxagliptin,saxagliptin,1039,False,authorised,A10BH03,False,False,False,False,False,False,False,9/30/09,,AstraZeneca AB,Drugs used in diabetes,,12/6/21,21.0,"Add-on combination therapyOnglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.",,2017-08-17T00:00:00Z,2022-12-15T17:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza
human,Imfinzi,"Carcinoma, Non-Small-Cell Lung",durvalumab,durvalumab,4771,False,authorised,L01XC28,True,False,False,False,False,False,False,9/21/18,,AstraZeneca AB,Antineoplastic agents,7/26/18,12/13/22,14.0,"Imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non‑small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum‑based chemoradiation therapy.",,2018-10-30T16:30:00Z,2022-12-15T11:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi
human,Repaglinide Krka,"Diabetes Mellitus, Type 2",repaglinide,repaglinide,1066,False,authorised,A10BX02,False,True,False,False,False,False,False,11/3/09,,"Krka, d.d., Novo mesto",Drugs used in diabetes,7/23/09,12/13/22,8.0,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",,2017-10-27T00:00:00Z,2022-12-14T11:16:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka
human,Enyglid,"Diabetes Mellitus, Type 2",repaglinide,repaglinide,1065,False,authorised,A10BX02,False,True,False,False,False,False,False,10/13/09,,"Krka, d.d., Novo mesto",Drugs used in diabetes,,12/13/22,9.0,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",,2016-06-24T00:00:00Z,2022-12-14T11:12:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/enyglid
human,Symtuza,HIV Infections,"darunavir, cobicistat, emtricitabine, tenofovir alafenamide","darunavir, cobicistat, emtricitabine, tenofovir alafenamide",4391,False,authorised,J05,False,False,False,False,False,False,False,9/21/17,,Janssen-Cilag International NV,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",7/19/17,11/10/22,16.0,Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).Genotypic testing should guide the use of Symtuza.,,2017-07-06T15:34:00Z,2022-12-13T18:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/symtuza
human,Rezolsta,HIV Infections,"darunavir, cobicistat","darunavir, cobicistat",2819,False,authorised,J05,False,False,False,False,False,False,False,11/19/14,,Janssen-Cilag International N.V.,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",,11/10/22,15.0,"Rezolsta, is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older.Genotypic testing should guide the use of Rezolsta.",,2018-06-29T14:04:00Z,2022-12-13T18:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta
human,Eviplera,HIV Infections,"emtricitabine, rilpivirine, tenofovir disoproxil","emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate",2312,False,authorised,J05AR08,False,False,False,False,False,False,False,11/27/11,,Gilead Sciences International Ltd ,Antivirals for systemic use,,12/12/22,25.0,"Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.",,2018-07-19T00:00:00Z,2022-12-13T12:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera
human,Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.),"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol","formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate",4836,False,authorised,R03AL09,False,False,False,False,False,False,False,4/23/18,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases,",,12/9/22,4.0,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,,2018-04-23T14:02:00Z,2022-12-13T12:06:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/riarify
human,Steglatro,"Diabetes Mellitus, Type 2",ertugliflozin,ertugliflozin l-pyroglutamic acid,4315,False,authorised,A10BK04,True,False,False,False,False,False,False,3/21/18,,Merck Sharp & Dohme B.V.,"Sodium-glucose co-transporter 2 (SGLT2) inhibitors, Drugs used in diabetes",1/25/18,12/5/22,8.0,Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.in addition to other medicinal products for the treatment of diabetes.,,2018-04-26T12:07:00Z,2022-12-06T09:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/steglatro
human,Efavirenz/Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil","efavirenz, emtricitabine, tenofovir disoproxil succinate",4274,False,authorised,J05AR06,False,True,False,False,False,False,False,2/8/18,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,12/14/17,11/7/22,9.0,"Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",,2018-02-08T13:05:00Z,2022-12-05T10:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-krka
human,Xalkori,"Carcinoma, Non-Small-Cell Lung",crizotinib,crizotinib,2489,False,authorised,L01ED01,False,False,False,False,False,False,False,10/23/12,,Pfizer Europe MA EEIG,Antineoplastic agents,7/19/12,10/28/22,33.0,XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to,,2018-08-31T14:47:00Z,2022-12-02T12:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori
human,Lacosamide Accord,Epilepsy,lacosamide,lacosamide,4443,False,authorised,N03AX18,False,True,False,False,False,False,False,9/18/17,,Accord Healthcare S.L.U.,"Antiepileptics,",7/20/17,11/22/22,11.0,"Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.Lacosamide Accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.•         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.",,2018-04-04T12:01:00Z,2022-11-30T11:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-accord
human,Lumykras,"Carcinoma, Non-Small-Cell Lung",sotorasib,sotorasib,5522,False,authorised,L01XX73,True,False,False,True,False,False,False,1/6/22,,Amgen Europe BV,Antineoplastic agents,11/11/21,9/15/22,1.0,Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.,,2021-11-10T11:46:00Z,2022-11-29T16:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras
human,Kaletra,HIV Infections,"lopinavir, ritonavir","lopinavir, ritonavir",368,False,authorised,J05AR10,False,False,False,False,False,False,False,3/19/01,,AbbVie Deutschland GmbH  Co. KG,"Antivirals for systemic use, Protease inhibitors",12/14/00,10/27/22,60.0,"Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.",,2018-05-23T11:36:00Z,2022-11-29T13:19:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/kaletra
human,Tagrisso,"Carcinoma, Non-Small-Cell Lung",osimertinib,osimertinib mesilate,4124,False,authorised,L01XE,False,False,False,False,False,True,False,2/1/16,,AstraZeneca AB,"Other antineoplastic agents, Protein kinase inhibitors",12/17/15,10/6/22,17.0,TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations- the first-line treatment of adult patients NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.,,2018-08-31T11:58:00Z,2022-11-29T09:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso
human,Intelence,HIV Infections,etravirine,etravirine,900,False,authorised,J05AG04,False,False,False,False,False,False,False,8/28/08,,Janssen-Cilag International NV,"Non-nucleoside reverse transcriptase inhibitors, Antivirals for systemic use",,10/7/22,30.0,"Intelence, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced adult patients and in antiretroviral-treatment-experienced paediatric patients from six years of age.This indication is based on week-48 analyses from two phase-III trials in highly pretreated patients where Intelence was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48-week analyses of a single-arm, phase-II trial in antiretroviral-treatment-experienced paediatric patients.",,2017-07-13T10:40:00Z,2022-11-28T16:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/intelence
human,Genvoya,HIV Infections,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide","elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",4042,False,authorised,J05AR,False,False,False,False,False,False,False,11/19/15,,Gilead Sciences Ireland UC,Antivirals for systemic use,9/24/15,10/3/22,27.0,"Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.",,2018-07-26T12:09:00Z,2022-11-28T11:53:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya
human,Tasmar,Parkinson Disease,tolcapone,tolcapone,132,False,authorised,N04BX01,False,False,False,False,False,False,False,8/27/97,,Viatris Healthcare Limited,"Anti-Parkinson drugs, Other dopaminergic agents",,11/21/22,24.0,"Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.",,2018-08-08T00:00:00Z,2022-11-25T15:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tasmar
human,Rebetol,"Hepatitis C, Chronic",ribavirin,ribavirin,246,False,authorised,J05AP01,False,False,False,False,False,False,False,5/6/99,,Merck Sharp and Dohme B.V,"Antivirals for systemic use, Antivirals for treatment of HCV infections",,11/24/22,39.0,Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.,,2017-02-03T01:00:00Z,2022-11-24T17:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rebetol
human,Temybric Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol","fluticasone furoate, umeclidinium bromide, vilanterol trifenatate",5254,False,withdrawn,R03AL08,True,False,False,False,False,False,False,6/12/19,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases,",,12/11/21,4.0,Temybric Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).,,2019-09-23T15:30:00Z,2022-11-24T16:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta
human,Rekambys,HIV Infections,rilpivirine,rilpivirine,5060,False,authorised,J05AG05,True,False,False,False,False,False,False,12/17/20,,Janssen-Cilag International NV,Antivirals for systemic use,10/15/20,11/21/22,7.0,"Rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class.",,2021-01-04T16:14:00Z,2022-11-23T11:06:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
human,Fuzeon,HIV Infections,enfuvirtide,enfuvirtide,514,False,authorised,J05AX07,False,False,False,False,False,False,False,5/27/03,,Roche Registration GmbH,Antivirals for systemic use,,11/22/22,23.0,"Fuzeon is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse-transcriptase inhibitors and nucleoside reverse-transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens.In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different medicinal products. Where available, resistance testing may be appropriate.",,2018-04-06T02:00:00Z,2022-11-23T10:56:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/fuzeon
human,Elebrato Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol","fluticasone furoate, umeclidinium bromide, vilanterol trifenatate",4781,False,authorised,R03AL08,False,False,False,False,False,False,False,11/15/17,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases,",9/14/17,7/15/22,10.0,Elebrato Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.,,2018-05-30T16:47:00Z,2022-11-22T14:24:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/elebrato-ellipta
human,Anoro Ellipta (previously Anoro),"Pulmonary Disease, Chronic Obstructive","umeclidinium bromide, vilanterol","umeclidinium bromide, vilanterol trifenatate",2751,False,authorised,R03AL03,True,False,False,False,False,False,False,5/8/14,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases,",2/20/14,11/18/22,18.0,Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2017-07-13T13:57:00Z,2022-11-22T12:41:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta
human,Rolufta Ellipta (previously Rolufta),"Pulmonary Disease, Chronic Obstructive",umeclidinium,umeclidinium bromide,4654,False,authorised,R03BB07,True,False,False,False,False,False,False,3/20/17,,GlaxoSmithKline Trading Services Limited,"Drugs for obstructive airway diseases,",1/26/17,11/9/22,11.0,"Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,",,2018-06-27T00:00:00Z,2022-11-21T18:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rolufta-ellipta
human,Laventair Ellipta (previously Laventair),"Pulmonary Disease, Chronic Obstructive","umeclidinium bromide, vilanterol","umeclidinium bromide, vilanterol",3754,False,authorised,R03AL03,True,False,False,False,False,False,False,5/8/14,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases,",2/20/14,11/9/22,17.0,Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2017-04-21T00:00:00Z,2022-11-21T16:37:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/laventair-ellipta
human,Zepatier,"Hepatitis C, Chronic","elbasvir, grazoprevir","elbasvir, grazoprevir",4126,False,authorised,J05AP54,False,False,False,False,False,False,False,7/22/16,,Merck Sharp & Dohme B.V.,"Direct acting antivirals, Antivirals for systemic use, Antivirals for treatment of HCV infections",5/26/16,11/21/22,13.0,"ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.",,2018-06-15T12:03:00Z,2022-11-21T11:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier
human,Janumet,"Diabetes Mellitus, Type 2","sitagliptin, metformin","sitagliptin, metformin hydrochloride",861,False,authorised,A10BD07,False,False,False,False,False,False,False,7/16/08,2/18/09,Merck Sharp & Dohme B.V.,Drugs used in diabetes,4/24/08,9/16/21,29.0,"For patients with type 2 diabetes mellitus:Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Janumet is indicated as triple combination therapy with a PPAR  agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR  agonist.Janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.",,2018-06-29T00:00:00Z,2022-11-18T14:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/janumet
human,Evotaz,HIV Infections,"atazanavir, cobicistat","cobicistat, atazanavir",3904,False,authorised,J05AR15,False,False,False,False,False,False,False,7/13/15,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,5/21/15,11/10/22,13.0,EVOTAZ is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).,,2018-02-22T16:57:00Z,2022-11-17T18:23:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz
human,Ozempic,Diabetes Mellitus,semaglutide,semaglutide,4174,False,authorised,A10BJ06,True,False,False,False,False,False,False,2/8/18,,Novo Nordisk A/S,Drugs used in diabetes,11/9/17,9/21/22,9.0,"Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",,2018-05-31T14:13:00Z,2022-11-16T14:44:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
human,Incruse Ellipta (previously Incruse),"Pulmonary Disease, Chronic Obstructive",umeclidinium bromide,umeclidinium bromide,2809,False,authorised,R03BB07,True,False,False,False,False,False,False,4/28/14,,GlaxoSmithKline (Ireland) Limited,"Drugs for obstructive airway diseases,",2/20/14,11/9/22,18.0,"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,",,2017-07-13T12:05:00Z,2022-11-15T13:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse
human,Exforge,Hypertension,"amlodipine, valsartan","valsartan, amlodipine (as amlodipine besilate)",716,False,authorised,C09DB01,False,False,False,False,False,False,False,1/16/07,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,11/10/22,31.0,Treatment of essential hypertension.Exforge is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,,2018-06-25T14:43:00Z,2022-11-11T15:08:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/exforge
human,Dafiro,Hypertension,"amlodipine, valsartan","amlodipine, valsartan",776,False,authorised,C09DB01,False,False,False,False,False,False,False,1/15/07,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,11/10/22,30.0,"Treatment of essential hypertension., , Dafiro is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,",,2018-06-07T14:45:00Z,2022-11-11T14:47:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/dafiro
human,Copalia,Hypertension,"amlodipine, valsartan","valsartan, amlodipine (as amlodipine besilate)",774,False,authorised,C09DB01,False,False,False,False,False,False,False,1/15/07,,Novartis Europharm Limited,Agents acting on the renin-angiotensin system,,11/10/22,29.0,"Treatment of essential hypertension., , Copalia is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,",,2018-06-04T23:09:00Z,2022-11-11T14:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/copalia
human,Emtriva,HIV Infections,emtricitabine,emtricitabine,533,False,authorised,J05AF09,False,False,False,False,False,False,False,10/24/03,,Gilead Sciences Ireland UC,Antivirals for systemic use,,11/10/22,32.0,"Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents., , This indication is based on studies in treatment-naive patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens., , When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.,",,2018-07-24T17:15:00Z,2022-11-10T13:21:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
human,Icandra (previously Vildagliptin / metformin hydrochloride Novartis),"Diabetes Mellitus, Type 2","vildagliptin, metformin","vildagliptin, metformin hydrochloride",1050,False,authorised,A10BD08,False,False,False,False,False,False,False,11/30/08,,Novartis Europharm Limited,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,10/14/22,25.0,"Icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",,2018-04-12T00:00:00Z,2022-11-09T09:40:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/icandra-previously-vildagliptin-metformin-hydrochloride-novartis
human,Dovato,HIV Infections,"dolutegravir, lamivudine","dolutegravir sodium, lamivudine",4909,False,authorised,J05AR,False,False,False,False,False,False,False,6/10/22,,ViiV Healthcare B.V.,Antivirals for systemic use,4/26/19,9/22/22,12.0,"Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.,",,2019-09-04T11:36:00Z,2022-11-08T18:16:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/dovato
human,Eucreas,"Diabetes Mellitus, Type 2","vildagliptin, metformin","vildagliptin, metformin hydrochloride",807,False,authorised,A10BD08,False,False,False,False,False,False,False,11/14/07,,Novartis Europharm Limited,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",,7/7/22,22.0,"Eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:, , , 	in patients who are inadequately controlled with metformin hydrochloride alone., 	in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets., 	in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control, ,",,2018-04-23T16:32:00Z,2022-11-08T17:31:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/eucreas
human,Triumeq,HIV Infections,abacavir sulfate / dolutegravir sodium / lamivudine,"dolutegravir sodium, lamivudine, abacavir (as sulfate)",2754,False,authorised,J05AR13,False,False,False,False,False,False,False,8/31/14,,ViiV Healthcare B.V.,Antivirals for systemic use,6/26/14,9/22/22,30.0,"Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.",,2018-07-12T12:02:00Z,2022-11-08T17:04:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/triumeq
human,Xiliarx,"Diabetes Mellitus, Type 2",vildagliptin,vildagliptin,1051,False,authorised,A10BH02,False,False,False,False,False,False,False,11/19/08,,Novartis Europharm Limited,Drugs used in diabetes,,7/7/22,22.0,"Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",,2018-04-26T14:00:00Z,2022-11-08T14:17:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xiliarx
human,Darunavir Mylan,HIV Infections,darunavir,darunavir,4068,False,authorised,J05AE10,False,True,False,False,False,False,False,1/3/17,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,9/14/16,11/3/22,12.0,"Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.2). Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10⁶/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).",,2018-07-12T11:59:00Z,2022-11-04T12:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-mylan
human,Micardis,Hypertension,telmisartan,telmisartan,209,False,authorised,C09CA07,False,False,False,False,False,False,False,12/16/98,,Boehringer Ingelheim International GmbH,"Angiotensin II antagonists, plain",,10/31/22,27.0,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.",,2018-05-22T00:00:00Z,2022-11-03T09:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/micardis
human,MicardisPlus,Hypertension,,"telmisartan, hydrochlorothiazide",413,False,authorised,C09DA07,False,False,False,False,False,False,False,4/19/02,,Boehringer Ingelheim International GmbH,Agents acting on the renin-angiotensin system,,10/31/22,33.0,"Treatment of essential hypertension.MicardisPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.MicardisPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",,2017-04-06T00:00:00Z,2022-11-03T09:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/micardisplus
human,Edurant,HIV Infections,rilpivirine,rilpivirine hydrochloride,2264,False,authorised,J05AG05,False,False,False,False,False,False,False,11/28/11,,Janssen-Cilag International N.V.   ,Antivirals for systemic use,,10/28/22,20.0,"Edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in antiretroviral treatment‑naïve patients 12 years of age and older with a viral load ≤ 100,000 HIV‑1 RNA copies/ml., , As with other antiretroviral medicinal products, genotypic resistance testing should guide the use of Edurant.,",,2018-05-08T17:00:00Z,2022-10-28T14:57:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/edurant
human,Sitagliptin SUN,"Diabetes Mellitus, Type 2",sitagliptin fumarate,sitagliptin fumarate,5741,False,authorised,A10BH01,False,True,False,False,False,False,False,12/9/21,,Sun Pharmaceutical Industries Europe B.V.,Drugs used in diabetes,10/14/21,7/8/22,1.0,"For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Sitagliptin SUN is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.",,2021-10-12T10:10:00Z,2022-10-27T10:50:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-sun
human,Galvus,"Diabetes Mellitus, Type 2",vildagliptin,vildagliptin,771,False,authorised,A10BH02,False,False,False,False,False,False,False,9/25/07,,Novartis Europharm Limited,Drugs used in diabetes,7/19/07,7/7/22,22.0,"Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control",,2018-04-26T00:00:00Z,2022-10-26T15:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/galvus
human,Thalidomide Lipomed,Multiple Myeloma,thalidomide,thalidomide,5715,False,authorised,L04AX02,False,False,False,False,False,False,False,9/19/22,,Lipomed GmbH,Immunosuppressants,7/21/22,,,"Thalidomide Lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.Thalidomide Lipomed is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme (see section 4.4).",,2022-07-18T14:13:00Z,2022-10-20T14:31:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed
human,Lorviqua,"Carcinoma, Non-Small-Cell Lung",lorlatinib,lorlatinib,4646,False,authorised,L01ED05,True,False,False,True,False,False,False,5/6/19,,Pfizer Europe MA EEIG,"Antineoplastic agents, Protein kinase inhibitors",2/28/19,4/4/22,10.0,", 	, 		, 			, 			Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor., , 			Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC whose disease has progressed after:, , 			, 				alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or, 				crizotinib and at least one other ALK TKI., 			, 			, 		, 	, ,",,2019-06-17T16:40:00Z,2022-10-20T10:08:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua
human,Isentress,HIV Infections,raltegravir,raltegravir,860,False,authorised,J05AJ01,False,False,False,False,False,True,False,12/19/07,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,11/15/07,10/17/22,42.0,Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.,,2018-06-07T00:00:00Z,2022-10-20T08:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/isentress
human,Invirase,HIV Infections,saquinavir,saquinavir,113,False,authorised,J05AE01,False,False,False,False,False,False,False,10/3/96,,Roche Registration GmbH,Antivirals for systemic use,,10/17/22,49.0,Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.,,2018-08-13T00:00:00Z,2022-10-20T07:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/invirase
human,Glubrava,"Diabetes Mellitus, Type 2","pioglitazone, metformin","metformin hydrochloride, pioglitazone hydrochloride",893,False,withdrawn,A10BD05,False,False,False,False,False,False,False,12/11/07,,Takeda Pharma A/S,Drugs used in diabetes,,2/4/21,19.0,"Glubrava is indicated as second line treatment of type-2-diabetes-mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2017-11-10T01:00:00Z,2022-10-18T16:15:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava
human,Norvir,HIV Infections,ritonavir,ritonavir,127,False,authorised,J05AE03,False,False,False,False,False,False,False,8/25/96,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,5/23/96,10/17/22,68.0,Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).,,2018-05-24T00:00:00Z,2022-10-18T10:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
human,Reyataz,HIV Infections,atazanavir sulfate,atazanavir (as sulfate),494,False,authorised,J05AE08,False,False,False,False,False,False,False,3/1/04,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,,10/17/22,53.0,"Reyataz capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).The choice of Reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history (see sections 4.4 and 5.1).Reyataz oral powder, co-administered with low dose ritonavir, is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients at least 3 months of age and weighing at least 5 kg (see section 4.2).Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 PI mutations). The choice of Reyataz in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history (see sections 4.4 and 5.1).",,2018-02-22T01:00:00Z,2022-10-17T13:45:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz
human,Glidipion (previously Pioglitazone Actavis Group),"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2558,False,withdrawn,A10BG03,False,True,False,False,False,False,False,3/15/12,,Actavis Group PTC ehf   ,Drugs used in diabetes,,6/11/20,8.0,"Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2017-07-28T00:00:00Z,2022-10-17T11:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion
human,Sustiva,HIV Infections,efavirenz,efavirenz,249,False,authorised,J05AG03,False,False,False,False,False,False,False,5/28/99,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,,10/13/22,46.0,"Sustiva is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (HIV-1)-infected adults, adolescents and children three years of age and older.Sustiva has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease-inhibitor (PI)-containing regimens. Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing Sustiva.",,2017-12-15T14:45:00Z,2022-10-17T10:57:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sustiva
human,Glustin,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,286,False,withdrawn,A10BG03,False,False,False,False,False,False,False,10/11/00,,Takeda Pharma A/S,Drugs used in diabetes,,2/4/21,28.0,"Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2016-05-26T02:00:00Z,2022-10-17T10:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/glustin
human,Ritonavir Mylan,HIV Infections,ritonavir,ritonavir,4549,False,authorised,J05AE03,False,True,False,False,False,False,False,11/9/17,,Mylan S.A.S,Antivirals for systemic use,9/14/17,8/22/22,13.0,Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).,,2018-05-03T16:47:00Z,2022-10-12T14:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ritonavir-mylan
human,Blenrep,Multiple Myeloma,belantamab mafodotin,belantamab mafodotin,4935,False,authorised,L01XC39,True,False,False,True,False,False,True,8/25/20,,GlaxoSmithKline (Ireland) Limited,Antineoplastic agents,7/23/20,9/26/22,4.0,"Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.",,2020-09-17T10:06:00Z,2022-10-12T08:33:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep
human,Vildagliptin / Metformin hydrochloride Accord,"Diabetes Mellitus, Type 2",vildagliptin / metformin hydrochloride,"metformin hydrochloride, vildagliptin",5738,False,authorised,A10BD08,True,True,False,False,False,False,False,3/24/22,,Accord Healthcare S.L.U.,Drugs used in diabetes,12/16/21,10/5/22,1.0,"Vildagliptin/Metformin hydrochloride Accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone.- in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.- in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).",,2021-12-14T15:04:00Z,2022-10-05T13:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord
human,Lenalidomide Mylan,Multiple Myeloma,lenalidomide,lenalidomide,5306,False,authorised,L04AX07,False,True,False,False,False,False,False,12/18/20,,Mylan Ireland Limited,Immunosuppressants,10/15/20,10/4/22,7.0,"Multiple myelomaLenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).",,2021-01-07T18:14:00Z,2022-10-05T10:12:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-mylan
human,Amlodipine  / Valsartan Mylan,Hypertension,"amlodipine, valsartan","amlodipine besilate, valsartan",4037,False,authorised,C09DB01,False,True,False,False,False,False,False,3/22/16,,Mylan Pharmaceuticals Limited,Agents acting on the renin-angiotensin system,1/28/16,9/29/22,10.0,Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,,2018-02-26T13:02:00Z,2022-09-30T16:49:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/amlodipine-valsartan-mylan
human,Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop),Hypertension,"irbesartan, hydrochlorothiazide","irbesartan, hydrochlorothiazide",783,False,authorised,C09DA04,False,False,False,False,False,False,False,1/18/07,,sanofi-aventis groupe ,Agents acting on the renin-angiotensin system,,9/27/22,33.0,Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,,2017-08-28T00:00:00Z,2022-09-28T16:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-zentiva-previously-irbesartan-hydrochlorothiazide-winthrop
human,Irbesartan Zentiva (previously Irbesartan Winthrop),Hypertension,irbesartan,irbesartan,785,False,authorised,C09CA04,False,False,False,False,False,False,False,1/19/07,,Zentiva k.s.,Agents acting on the renin-angiotensin system,1/19/07,9/27/22,28.0,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.,,2017-08-02T00:00:00Z,2022-09-28T11:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-zentiva
human,Trizivir,HIV Infections,abacavir (as sulfate) / lamivudine / zidovudine,"abacavir (as sulfate), lamivudine, zidovudine",338,False,authorised,J05AR04,False,False,False,False,False,False,False,12/27/00,,ViiV Healthcare BV,Antivirals for systemic use,9/21/00,8/11/22,42.0,"Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults.This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.The demonstration of the benefit of Trizivir is mainly based on results of studies performed in treatment naive patients or moderately antiretroviral experienced patients with non-advanced disease.In patients with high viral load (>100,000 copies/ml) choice of therapy needs special consideration.Overall, the virologic suppression with this triple nucleoside regimen could be inferior to that obtained with other multitherapies notably including boosted protease inhibitors or non-nucleoside reverse-transcriptase inhibitors, therefore the use of Trizivir should only be considered under special circumstances (e.g. co-infection with tuberculosis).Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir (see 'management after an interruption of Trizivir therapy'). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing.",,2018-01-25T16:42:00Z,2022-09-27T12:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trizivir
human,Atazanavir Mylan,HIV Infections,atazanavir,atazanavir (as sulfate),4048,False,authorised,J05AE08,False,True,False,False,False,False,False,8/22/16,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,6/23/16,9/22/22,12.0,"Atazanavir Mylan, co-administered with low dose ritonavir, is indicated for the treatment of HIV 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). There are very limited data available from children aged 6 to less than 18 years.The choice of Atazanavir Mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.",,2018-05-03T17:20:00Z,2022-09-26T15:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/atazanavir-mylan
human,Tenofovir disoproxil Mylan,HIV Infections,tenofovir disoproxil,tenofovir disoproxil,4049,False,authorised,J05AF07,False,True,False,False,False,False,False,12/8/16,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,10/13/16,8/29/22,16.0,"HIV-1 infectionTenofovir disoproxil 245 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults.In adults, the demonstration of the benefit of tenofovir disoproxil in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Tenofovir disoproxil 245 mg film-coated tablets are also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionTenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.evidence of lamivudine-resistant hepatitis B virus.decompensated liver disease.Tenofovir disoproxil 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.",,2017-11-27T13:00:00Z,2022-09-20T08:25:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-mylan
human,Tenofovir disoproxil Zentiva,HIV Infections,tenofovir disoproxil,tenofovir disoproxil phosphate,4120,False,authorised,J05AF07,False,True,False,False,False,False,False,9/15/16,,Zentiva k.s.,Antivirals for systemic use,7/21/16,9/15/22,12.0,"HIV‑1 infection, , Tenofovir disoproxil Zentiva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV‑1 infected adults., , In adults, the demonstration of the benefit of tenofovir disoproxil in HIV‑1 infection is based on results of one study in treatment‑naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre‑treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml)., , Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV‑1 infected adolescents, with NRTI (nucleotide reverse transcriptase inhibitor) resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years., , The choice of Tenofovir disoproxil Zentiva to treat antiretroviral‑experienced patients with HIV‑1 infection should be based on individual viral resistance testing and/or treatment history of patients., , Hepatitis B infection, , Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adults with:, , , 	compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1);, 	evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1);, 	decompensated liver disease (see sections 4.4, 4.8 and 5.1)., , , Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:, , , 	compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1)., ,",,2018-01-18T13:04:00Z,2022-09-15T17:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tenofovir-disoproxil-zentiva
human,Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil","efavirenz, emtricitabine, tenofovir disoproxil maleate",4240,False,authorised,J05AR06,False,True,False,False,False,False,False,9/5/17,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,6/22/17,8/22/22,13.0,"Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan prior to initiation of their first antiretroviral treatment regimen., , The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients., , No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.,",,2018-08-15T12:11:00Z,2022-09-14T16:41:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-mylan
human,PritorPlus,Hypertension,"telmisartan, hydrochlorothiazide","telmisartan, hydrochlorothiazide",414,False,authorised,C09DA07,False,False,False,False,False,False,False,4/22/02,,Bayer AG,Agents acting on the renin-angiotensin system,,8/24/22,37.0,"Treatment of essential hypertension.PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",,2018-04-13T00:00:00Z,2022-09-14T10:15:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pritorplus
human,Kinzalkomb,Hypertension,"telmisartan, hydrochlorothiazide","telmisartan, hydrochlorothiazide",415,False,authorised,C09DA07,False,False,False,False,False,False,False,4/19/02,,Bayer AG,Agents acting on the renin-angiotensin system,,8/24/22,39.0,"Treatment of essential hypertension.Kinzalkomb fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.Kinzalkomb fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on Kinzalkomb (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.",,2018-04-12T00:00:00Z,2022-09-14T09:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/kinzalkomb
human,Vipdomet,"Diabetes Mellitus, Type 2","alogliptin, metformin","alogliptin benzoate, metformin hydrochloride",2654,False,authorised,A10BD13,False,False,False,False,False,False,False,9/18/13,,Takeda Pharma A/S,"Combinations of oral blood glucose lowering drugs, Drugs used in diabetes",7/25/13,9/7/22,10.0,"Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:, , , 	as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;, 	in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;, 	in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control., ,",,2017-10-16T12:32:00Z,2022-09-09T16:07:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vipdomet
human,Incresync,"Diabetes Mellitus, Type 2","alogliptin, pioglitazone","alogliptin, pioglitazone",2178,False,authorised,A10BD09,False,False,False,False,False,False,False,9/19/13,,Takeda Pharma A/S,"Drugs used in diabetes, Combinations of oral blood glucose lowering drugs",7/25/13,9/7/22,13.0,"Incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus:, , , 	as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, 	in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone., , , In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination., , After initiation of therapy with Incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4).,",,2018-05-25T02:00:00Z,2022-09-09T12:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/incresync
human,Ontozry,Epilepsy,cenobamate,cenobamate,5377,False,authorised,N03AX,True,False,False,False,False,False,False,3/26/21,,Angelini Pharma S.p.A,"Antiepileptics,",,7/7/22,4.0,"Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.,",,2021-04-13T15:46:00Z,2022-09-08T08:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry
human,Jardiance,"Diabetes Mellitus, Type 2",empagliflozin,empagliflozin,2677,False,authorised,A10BK03,False,False,False,False,False,False,False,5/22/14,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,3/20/14,7/21/22,26.0,"Type 2 diabetes mellitus, , Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance - in addition to other medicinal products for the treatment of diabetes For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1., , , , Heart failure, , Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure.,",,2018-05-31T15:23:00Z,2022-09-06T13:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance
human,Suliqua,"Diabetes Mellitus, Type 2","insulin glargine, lixisenatide","insulin glargine, lixisenatide",4243,False,authorised,A10AE,False,False,False,False,False,False,False,1/11/17,,Sanofi Winthrop Industrie,Drugs used in diabetes,11/10/16,8/22/22,9.0,Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.,,2017-09-14T13:59:00Z,2022-09-05T15:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/suliqua
human,Insuman,Diabetes Mellitus,insulin human,insulin human,201,False,authorised,"A10AB01, A10AC01",False,False,False,False,False,False,False,2/21/97,,Sanofi-aventis Deutschland GmbH,Drugs used in diabetes,10/16/96,9/1/22,32.0,"Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.",,2018-04-03T02:00:00Z,2022-09-01T16:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/insuman
human,Sitagliptin / Metformin hydrochloride Accord,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride","metformin hydrochloride, sitagliptin hydrochloride monohydrate",5850,False,authorised,A10BD07,False,True,False,False,False,False,False,7/22/22,,Accord Healthcare S.L.U.,Drugs used in diabetes,5/19/22,8/31/22,1.0,"For adult patients with type 2 diabetes mellitus:, , , 	It is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin., 	It is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea., 	It is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist., 	It is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control., ,",,2022-08-03T17:20:00Z,2022-09-01T11:29:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-accord
human,Irbesartan/Hydrochlorothiazide Teva,Hypertension,"irbesartan, hydrochlorothiazide","irbesartan, hydrochlorothiazide",1112,False,authorised,C09DA04,False,True,False,False,False,False,False,11/26/09,,Teva B.V. ,Agents acting on the renin-angiotensin system,9/24/09,8/30/22,21.0,"Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,",,2017-11-07T01:00:00Z,2022-08-31T08:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-teva
human,Pioglitazone Teva Pharma,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2410,False,withdrawn,A10BG03,False,True,False,False,False,False,False,3/26/12,,Teva Pharma B.V.,Drugs used in diabetes,1/19/12,6/21/21,13.0,"Pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy:, , , 	in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance., , , Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance., , After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,",,2018-01-31T13:00:00Z,2022-08-30T17:14:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-teva-pharma
human,Ziagen,HIV Infections,abacavir,abacavir,252,False,authorised,J05AF06,False,False,False,False,False,False,False,7/8/99,,ViiV Healthcare B.V.,Antivirals for systemic use,3/25/99,8/11/22,46.0,"Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children., , The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy., , Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.,",,2018-03-01T07:09:00Z,2022-08-29T14:29:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen
human,Epivir,HIV Infections,lamivudine,lamivudine,107,False,authorised,J05AF05,False,False,False,False,False,False,False,8/8/96,,ViiV Healthcare BV,Antivirals for systemic use,,8/11/22,50.0,"Epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.,",,2018-03-05T01:00:00Z,2022-08-29T13:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/epivir
human,Combivir,HIV Infections,"lamivudine, zidovudine","lamivudine, zidovudine",190,False,authorised,J05AR01,False,False,False,False,False,False,False,3/18/98,,ViiV Healthcare BV,Antivirals for systemic use,11/19/97,8/11/22,37.0,"Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.,",,2018-01-25T01:09:00Z,2022-08-29T13:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/combivir
human,Bydureon,"Diabetes Mellitus, Type 2",exenatide,exenatide,2020,False,authorised,A10BJ01,False,False,False,False,False,False,False,6/17/11,,AstraZeneca AB,Drugs used in diabetes,4/14/11,7/14/22,23.0,"Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:MetforminSulphonylureaThiazolidinedioneMetformin and sulphonylureaMetformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.",,2017-11-10T12:36:00Z,2022-08-26T14:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon
human,Ontilyv,Parkinson Disease,opicapone,opicapone,5782,False,authorised,"N04, N04BX04",False,False,False,False,False,False,False,2/21/22,,Bial Portela & Companhia S.A.,Anti-Parkinson drugs,12/16/21,8/24/22,1.0,"Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.,",,2021-12-14T14:26:00Z,2022-08-25T16:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv
human,Sunlenca,HIV Infections,lenacapavir,lenacapavir sodium,5638,False,authorised,J05AX,True,False,False,False,False,False,False,8/17/22,,Gilead Sciences Ireland Unlimited Company,Antivirals for systemic use,6/23/22,,,"Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1)., , Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1).,",,2022-06-22T16:39:00Z,2022-08-25T15:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca
human,Daxas,"Pulmonary Disease, Chronic Obstructive",roflumilast,roflumilast,1179,False,authorised,R03DX07,True,False,False,False,False,False,False,7/5/10,,AstraZeneca AB,"Drugs for obstructive airway diseases,",4/22/10,8/25/22,19.0,"Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,",,2018-04-23T00:00:00Z,2022-08-25T15:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/daxas
human,Byetta,"Diabetes Mellitus, Type 2",exenatide,exenatide,698,False,authorised,A10BJ01,False,False,False,False,False,False,False,11/20/06,,AstraZeneca AB,Drugs used in diabetes,,7/14/22,27.0,"Byetta is indicated for treatment of type-2 diabetes mellitus in combination with:, , , 	metformin;, 	sulphonylureas;, 	thiazolidinediones;, 	metformin and a sulphonylurea;, 	metformin and a thiazolidinedione;, , , in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. Byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.,",,2018-06-26T02:00:00Z,2022-08-25T14:19:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/byetta
human,Telzir,HIV Infections,fosamprenavir,fosamprenavir calcium,534,False,authorised,J05AE07,False,False,False,False,False,False,False,7/12/04,,ViiV Healthcare BV,Antivirals for systemic use,,8/19/22,48.0,"Telzir in combination with low-dose ritonavir is indicated for the treatment of human-immunodeficiency-virus-type-1-infected adults, adolescents and children of six years and above in combination with other antiretroviral medicinal products., , In moderately antiretroviral-experienced adults, Telzir in combination with low-dose ritonavir has not been shown to be as effective as lopinavir / ritonavir. No comparative studies have been undertaken in children or adolescents., , In heavily pretreated patients, the use of Telzir in combination with low-dose ritonavir has not been sufficiently studied., , In protease-inhibitor-experienced patients, the choice of Telzir should be based on individual viral resistance testing and treatment history.,",,2017-03-10T01:00:00Z,2022-08-23T10:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/telzir
human,Kivexa,HIV Infections,"abacavir, lamivudine","abacavir, lamivudine",581,False,authorised,J05AR02,False,False,False,False,False,False,False,12/16/04,,ViiV Healthcare BV,"Antivirals for treatment of HIV infections, combinations, Antivirals for systemic use",,8/19/22,36.0,"Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg., , Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.,",,2018-01-25T01:00:00Z,2022-08-23T09:38:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa
human,Aptivus,HIV Infections,tipranavir,tipranavir,631,False,authorised,J05AE09,False,False,False,False,False,False,False,10/25/05,,Boehringer Ingelheim International GmbH,Antivirals for systemic use,7/27/05,7/28/22,42.0,"Aptivus, co-administered with low-dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pretreated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.This indication is based on the results of two phase-III studies, performed in highly pretreated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase-II study investigating pharmacokinetics, safety and efficacy of Aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of Aptivus. Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to Aptivus, co-administered with low-dose ritonavir.",,2017-11-10T01:00:00Z,2022-08-23T09:37:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/aptivus
human,Viramune,HIV Infections,nevirapine,nevirapine,183,False,authorised,J05AG01,False,False,False,False,False,False,False,2/4/98,,Boehringer Ingelheim International GmbH,Antivirals for systemic use,10/22/97,8/5/22,43.0,"Tablets and oral suspensionViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents, and children of any age.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsViramune is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults, adolescents and children three years and above and able to swallow tablets.Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.Most of the experience with Viramune is in combination with nucleoside reverse-transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing.",,2018-05-01T00:00:00Z,2022-08-23T09:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/viramune
human,Rukobia,HIV Infections,fostemsavir,fostemsavir trometamol,5011,False,authorised,J05AX,True,False,False,False,False,False,False,2/4/21,,ViiV Healthcare B.V.,Antivirals for systemic use,12/10/20,8/19/22,3.0,"Rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.,",,2021-02-12T15:46:00Z,2022-08-22T17:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rukobia
human,Celsentri,HIV Infections,maraviroc,maraviroc,811,False,authorised,J05AX09,False,False,False,False,False,False,False,9/18/07,,ViiV Healthcare B.V.,Antivirals for systemic use,7/19/07,8/19/22,28.0,"Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable,",,2018-04-12T10:13:00Z,2022-08-22T15:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/celsentri
human,Exviera,"Hepatitis C, Chronic",dasabuvir,dasabuvir sodium,3837,False,authorised,J05AP09,False,False,False,False,False,True,False,1/14/15,,AbbVie Ltd,Antivirals for systemic use,11/20/04,8/12/22,25.0,Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.,,2018-04-10T11:45:00Z,2022-08-12T15:50:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/exviera
human,Viekirax,"Hepatitis C, Chronic","ombitasvir, paritaprevir, ritonavir","ombitasvir, paritaprevir, ritonavir",3839,False,authorised,J05AP53,False,False,False,False,False,False,False,1/14/15,,AbbVie Deutschland GmbH  Co. KG,Antivirals for systemic use,11/20/14,8/12/22,27.0,"Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults., , For hepatitis C virus (HCV) genotype specific activity.,",,2018-08-31T11:59:00Z,2022-08-12T15:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax
human,Rybelsus,"Diabetes Mellitus, Type 2",semaglutide,semaglutide,4953,False,authorised,A10BJ06,True,False,False,False,False,False,False,4/3/20,,Novo Nordisk A/S,Drugs used in diabetes,1/30/20,6/23/22,4.0,"Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise, , , 	as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, 	in combination with other medicinal products for the treatment of diabetes., , , For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.,",,2020-05-27T11:50:00Z,2022-07-26T17:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus
human,Trelegy Ellipta,"Pulmonary Disease, Chronic Obstructive","fluticasone furoate, umeclidinium, vilanterol","fluticasone furoate, umeclidinium bromide, vilanterol trifenatate",4363,False,authorised,R03AL08,False,False,False,False,False,False,False,11/15/17,,GlaxoSmithKline Trading Services,"Drugs for obstructive airway diseases,",9/14/17,7/15/22,9.0,"Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.,",,2018-05-30T16:47:00Z,2022-07-25T12:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta
human,Sitagliptin Accord,"Diabetes Mellitus, Type 2",sitagliptin,sitagliptin hydrochloride,5598,False,authorised,A10BH01,False,True,False,False,False,False,False,4/25/22,,Accord Healthcare S.L.U.,Drugs used in diabetes,2/24/22,4/25/22,,"For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control:, , as monotherapy:, - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance., , as dual oral therapy in combination with:, - metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control., - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance., - a peroxisome proliferator-activated receptor gamma (PPARy) agonist (i.e. a thiazolidinedione) when use of a PPARy agonist is appropriate and when diet and exercise plus the PPARy agonist alone do not provide adequate glycaemic control., , as triple oral therapy in combination with:, - a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control., - a PPARy agonist and metformin when use of a PPARy agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control., , Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.,",,2022-02-22T14:50:00Z,2022-07-21T16:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-accord
human,Zonisamide Mylan,Epilepsy,zonisamide,zonisamide,4127,False,authorised,N03AX15,False,True,False,False,False,False,False,3/31/16,,Mylan Pharmaceuticals Limited,"Antiepileptics,",1/28/16,7/14/22,8.0,", 	Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;, 	adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above., ,",,2018-03-26T12:02:00Z,2022-07-15T11:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan
human,Bevespi Aerosphere,"Pulmonary Disease, Chronic Obstructive","glycopyrronium, formoterol fumarate dihydrate","glycopyrronium, formoterol fumarate dihydrate",4245,False,authorised,R03AL07,False,False,False,False,False,False,False,12/18/18,,AstraZeneca AB,formoterol and glycopyrronium bromide,10/18/18,7/13/22,5.0,"Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,",,2019-02-05T15:47:00Z,2022-07-13T15:46:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere
human,Jalra,"Diabetes Mellitus, Type 2",vildagliptin,vildagliptin,1048,False,authorised,A10BH02,False,False,False,False,False,False,False,11/19/08,,Novartis Europharm Limited,"Dipeptidyl peptidase 4 (DPP-4) inhibitors, Drugs used in diabetes",9/25/08,5/4/22,23.0,"Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:, , , 	as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance., 	in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations)., ,",,2018-04-26T00:09:00Z,2022-07-12T17:41:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/jalra
human,Crixivan,HIV Infections,indinavir,indinavir sulfate ethanolate,128,False,withdrawn,J05AE02,False,False,False,False,False,False,False,10/4/96,,Merck Sharp & Dohme B.V.,Antivirals for systemic use,,8/3/18,39.0,"Crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.,",,2018-06-19T22:00:00Z,2022-07-12T09:56:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/crixivan
human,Darzalex,Multiple Myeloma,daratumumab,daratumumab,4077,False,authorised,L01FC01,False,False,False,False,False,True,True,5/20/16,,Janssen-Cilag International N.V.,"Antineoplastic agents, monoclonal antibodies and antibody drug conjugates",3/31/16,6/30/22,19.0,"Multiple Myeloma, , Darzalex is indicated:, , , 	 in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant., 	in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant., 	in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy., 	in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1)., 	as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy., , , AL Amyloidosis, , DARZALEX is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis.,",,2018-08-31T15:16:00Z,2022-07-11T13:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex
human,Levetiracetam Teva,Epilepsy,levetiracetam,levetiracetam,2316,False,authorised,N03AX14,False,True,False,False,False,False,False,8/25/11,,Teva B.V.,Nervous system,5/19/11,7/6/22,19.0,"Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Teva is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2018-01-31T13:11:00Z,2022-07-06T12:57:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-teva
human,Iressa,"Carcinoma, Non-Small-Cell Lung",gefitinib,gefitinib,1016,False,authorised,L01XE02,False,False,False,False,False,False,False,6/24/09,,AstraZeneca AB,Antineoplastic agents,,7/4/22,15.0,"Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.,",,2018-04-23T00:00:00Z,2022-07-05T16:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/iressa
human,Levetiracetam Actavis,Epilepsy,levetiracetam,levetiracetam,2355,False,authorised,N03AX14,False,True,False,False,False,False,False,10/3/11,,Actavis Group PTC ehf,"Antiepileptics,",,6/29/22,18.0,"Levetiracetam Actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2018-03-21T13:41:00Z,2022-07-01T13:34:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-actavis
human,Ristfor,"Diabetes Mellitus, Type 2","sitagliptin, metformin hydrochloride","sitagliptin, metformin hydrochloride",1235,False,authorised,A10BD07,False,False,False,False,False,False,False,3/15/10,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,12/17/09,6/28/22,25.0,"For patients with type-2 diabetes mellitus:, , , 	Ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin., 	Ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea., 	Ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist., 	Ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control., ,",,2018-06-29T02:00:00Z,2022-07-01T12:12:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ristfor
human,Thalidomide BMS (previously Thalidomide Celgene),Multiple Myeloma,thalidomide,thalidomide,823,False,authorised,L04AX02,False,False,False,False,False,False,False,4/16/08,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,,12/13/21,30.0,"Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy., , Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).,",,2018-08-08T00:09:00Z,2022-07-01T11:17:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-celgene
human,Levetiracetam Actavis Group,Epilepsy,levetiracetam,levetiracetam,2305,False,authorised,N03AX14,False,True,False,False,False,False,False,12/4/11,,Actavis Group PTC ehf,"Antiepileptics,",,6/29/22,16.0,"Levetiracetam Actavis Group is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Actavis Group is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2018-03-20T14:00:00Z,2022-07-01T11:09:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-actavis-group
human,Ristaben,"Diabetes Mellitus, Type 2",sitagliptin,sitagliptin,1234,False,authorised,A10BH01,False,False,False,False,False,False,False,3/15/10,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,12/17/09,6/28/22,24.0,"For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:, , , 	as monotherapy:, 	, 		in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;, 	, 	, 	as dual oral therapy in combination with:, 	, 		metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;, 		a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;, 		a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;, 	, 	, 	as triple oral therapy in combination with:, 	, 		a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;, 		a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control., 	, 	, , , Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.,",,2018-05-22T11:39:00Z,2022-07-01T10:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ristaben
human,Januvia,"Diabetes Mellitus, Type 2",sitagliptin,sitagliptin,722,False,authorised,A10BH01,False,False,False,False,False,False,False,3/20/07,,Merck Sharp and Dohme B.V,Drugs used in diabetes,,9/2/21,30.0,"For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:, , , 	as monotherapy:, 	, 		in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;, 	, 	, 	as dual oral therapy in combination with:, 	, 		metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;, 		a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;, 		a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;, 		a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;, 	, 	, 	as triple oral therapy in combination with:, 	, 		a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;, 		a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control., 	, 	, , , Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.,",,2018-05-16T23:09:00Z,2022-06-30T16:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/januvia
human,Starlix,"Diabetes Mellitus, Type 2",nateglinide,nateglinide,335,False,withdrawn,A10BX03,False,False,False,False,False,False,False,4/3/01,,Novartis Europharm Limited,Drugs used in diabetes,,11/8/21,15.0,Nateglinide is indicated for combination therapy with metformin in type-2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.,,2018-05-08T11:58:00Z,2022-06-28T11:43:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/starlix
human,Levetiracetam Sun,Epilepsy,levetiracetam,levetiracetam,2051,False,authorised,N03AX14,False,True,False,False,False,False,False,12/14/11,,Sun Pharmaceutical Industries Europe B.V.,Other antiepileptics,10/20/11,6/23/22,17.0,Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.,,2018-07-24T16:35:00Z,2022-06-24T16:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun
human,Sitagliptin / Metformin hydrochloride Mylan,"Diabetes Mellitus, Type 2","sitagliptin hydrochloride monohydrate, metformin hydrochloride","sitagliptin hydrochloride monohydrate, metformin hydrochloride",5678,False,authorised,A10BD07,False,True,False,False,False,False,False,2/16/22,,Mylan Ireland Limited,Drugs used in diabetes,12/16/21,6/20/22,1.0,"For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride Mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Sitagliptin/Metformin hydrochloride Mylan is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Sitagliptin/Metformin hydrochloride Mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARg) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARg agonist.Sitagliptin/Metformin hydrochloride Mylan is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.",,2021-12-14T12:10:00Z,2022-06-21T14:45:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-metformin-hydrochloride-mylan
human,Gefitinib Mylan,"Carcinoma, Non-Small-Cell Lung",gefitinib,gefitinib,4826,False,authorised,L01XE02,False,True,False,False,False,False,False,9/27/18,,Mylan Pharmaceuticals Limited,"Antineoplastic agents, Protein kinase inhibitors",,6/15/22,5.0,Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with activating mutations of EGFR‑TK.,,2018-10-10T13:10:00Z,2022-06-17T15:18:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/gefitinib-mylan
human,Kyprolis,Multiple Myeloma,carfilzomib,carfilzomib,3790,False,authorised,L01XX45,False,False,False,False,False,True,True,11/19/15,,Amgen Europe B.V.,Antineoplastic agents,9/24/15,4/1/22,20.0,"Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.",,2018-06-04T14:07:00Z,2022-06-15T16:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis
human,Emtricitabine/Tenofovir disoproxil Krka d.d.,HIV Infections,"emtricitabine, tenofovir disoproxil","emtricitabine, tenofovir disoproxil succinate",4686,False,authorised,J05AR03,False,True,False,False,False,False,False,4/28/17,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,2/23/17,1/6/22,9.0,"Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.",,2018-07-25T09:04:00Z,2022-06-15T15:38:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka-dd
human,Levetiracetam Hospira,Epilepsy,levetiracetam,levetiracetam,2783,False,authorised,N03AX14,False,True,False,False,False,False,False,1/7/14,,Pfizer Europe MA EEIG,"Antiepileptics,",10/23/13,6/14/22,23.0,"Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible.",,2017-11-01T14:09:00Z,2022-06-15T11:23:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-hospira
human,Truvelog Mix 30,Diabetes Mellitus,insulin aspart,insulin aspart,5635,False,authorised,A10AD05,True,False,True,False,False,False,False,4/25/22,,sanofi-aventis groupe ,Drugs used in diabetes,2/24/22,4/25/22,,"Truvelog Mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.",,2022-02-23T16:01:00Z,2022-06-15T10:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/truvelog-mix-30
human,Levetiracetam ratiopharm,Epilepsy,levetiracetam,levetiracetam,2244,False,authorised,N03AX14,False,True,False,False,False,False,False,8/26/11,,ratiopharm GmbH,"Antiepileptics,",,6/8/22,14.0,"Levetiracetam ratiopharm is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam ratiopharm is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2017-08-10T14:15:00Z,2022-06-10T11:41:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-ratiopharm
human,Gavreto,"Carcinoma, Non-Small-Cell Lung",pralsetinib,pralsetinib,5413,False,authorised,L01XE,True,False,False,True,False,False,False,11/18/21,,Roche Registration GmbH ,Antineoplastic agents,9/16/21,6/9/22,3.0,Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.,,2021-09-14T15:16:00Z,2022-06-10T08:34:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto
human,Matever,Epilepsy,levetiracetam,levetiracetam,2024,False,authorised,N03AX14,False,True,False,False,False,False,False,10/3/11,,Pharmathen S.A.,"Antiepileptics,",,6/9/22,26.0,"Matever is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Matever is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2018-07-02T16:30:00Z,2022-06-09T15:56:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/matever
human,Lopinavir/Ritonavir Mylan,HIV Infections,"lopinavir, ritonavir","lopinavir, ritonavir",4025,False,authorised,J05AR10,False,True,False,False,False,False,False,1/14/16,,Mylan Pharmaceuticals Limited,Antivirals for systemic use,11/19/15,6/9/22,14.0,"Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.",,2018-06-14T15:19:00Z,2022-06-09T09:41:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lopinavir-ritonavir-mylan
human,Glyxambi,"Diabetes Mellitus, Type 2","empagliflozin, linagliptin","empagliflozin, linagliptin",3833,False,authorised,A10BD19,False,False,False,False,False,False,False,11/11/16,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,9/15/16,4/13/22,15.0,"Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.",,2018-08-03T12:11:00Z,2022-05-25T15:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi
human,Synjardy,"Diabetes Mellitus, Type 2","empagliflozin, metformin","empagliflozin, metformin",3770,False,authorised,A10BD20,False,False,False,False,False,False,False,5/27/15,,Boehringer Ingelheim,Drugs used in diabetes,3/26/15,3/24/22,24.0,"Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.",,2018-05-31T12:16:00Z,2022-05-25T15:34:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/synjardy
human,Actos,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,285,False,authorised,A10BG03,False,False,False,False,False,False,False,10/13/00,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,5/23/22,29.0,"Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.",,2016-05-26T00:00:00Z,2022-05-24T12:56:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/actos
human,Rasilez HCT,Hypertension,"aliskiren, hydrochlorothiazide","aliskiren, hydrochlorothiazide",964,False,withdrawn,C09XA52,False,False,False,False,False,False,False,1/16/09,,Noden Pharma DAC,Agents acting on the renin-angiotensin system,,12/20/21,17.0,"Treatment of essential hypertension in adults.Rasilez HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Rasilez HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",,2018-08-27T00:00:00Z,2022-05-20T16:17:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez-hct
human,Riltrava Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol fumarate dihydrate, glycopyrronium, budesonide","budesonide, formoterol fumarate dihydrate, glycopyrronium bromide",5311,False,authorised,R03AL11,False,False,False,False,False,False,False,1/6/22,,AstraZeneca AB,"Drugs for obstructive airway diseases,",11/11/21,5/19/22,1.0,Riltrava Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,,2021-11-10T14:47:00Z,2022-05-20T13:58:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/riltrava-aerosphere
human,Trixeo Aerosphere,"Pulmonary Disease, Chronic Obstructive","formoterol, glycopyrronium bromide, budesonide","formoterol fumarate dihydrate, glycopyrronium bromide, budesonide",4983,False,authorised,R03AL,False,False,False,False,False,False,False,12/9/20,,AstraZeneca AB,"Drugs for obstructive airway diseases,",10/15/20,5/19/22,3.0,Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.,,2021-01-05T16:16:00Z,2022-05-20T13:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trixeo-aerosphere
human,Alunbrig,"Carcinoma, Non-Small-Cell Lung",brigatinib,brigatinib,4248,False,authorised,L01XE43,True,False,False,False,False,False,False,11/22/18,,Takeda Pharma A/S,Antineoplastic agents,9/19/18,2/17/22,8.0,Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.,,2018-11-26T16:01:00Z,2022-05-18T11:47:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig
human,Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil","efavirenz, emtricitabine, tenofovir disoproxil phosphate",4250,False,authorised,J05AR06,False,True,False,False,False,False,False,7/17/17,,Zentiva k.s.,Antivirals for systemic use,5/18/17,5/17/22,8.0,"Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil.It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months.Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil.No data are currently available from clinical studies with combination efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.",,2018-01-09T13:32:00Z,2022-05-18T11:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-zentiva
human,Ongentys,Parkinson Disease,opicapone,opicapone,2790,False,authorised,N04,False,False,False,False,False,False,False,6/24/16,,"Bial - Portela  Cª, S.A.",Anti-Parkinson drugs,4/28/16,5/13/22,8.0,Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.,,2017-01-17T01:00:00Z,2022-05-13T16:53:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys
human,Tepmetko,"Carcinoma, Non-Small-Cell Lung",tepotinib,tepotinib hydrochloride monohydrate,5524,False,authorised,L01EX21,True,False,False,False,False,False,False,2/16/22,,Merck Europe B.V.,Antineoplastic agents,12/16/21,2/16/22,,"Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",,2022-05-05T10:13:00Z,,https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko
human,Toujeo (previously Optisulin),Diabetes Mellitus,insulin glargine,insulin glargine,309,False,authorised,A10AE04,False,False,False,False,False,False,False,6/26/00,,Sanofi-aventis Deutschland GmbH,Drugs used in diabetes,2/17/00,11/26/21,32.0,"Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.",,2017-10-26T23:09:00Z,2022-04-11T15:05:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/toujeo-previously-optisulin
human,Insulin lispro Sanofi,Diabetes Mellitus,insulin lispro,insulin lispro,4303,False,authorised,A10AB04,False,False,True,False,False,False,False,7/19/17,,Sanofi Winthrop Industrie,Drugs used in diabetes,5/17/17,3/28/22,7.0,For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus.,,2018-04-03T12:29:00Z,2022-04-07T15:21:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-lispro-sanofi
human,Tresiba,Diabetes Mellitus,insulin degludec,insulin degludec,2498,False,authorised,A10AE06,False,False,False,False,False,False,False,1/20/13,,Novo Nordisk A/S,Drugs used in diabetes,10/18/12,1/13/22,16.0,Treatment of diabetes mellitus in adults.,,2018-07-10T12:33:00Z,2022-04-05T11:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba
human,Farydak,Multiple Myeloma,panobinostat,panobinostat lactate anhydrous,3725,False,authorised,L01XH03,False,False,False,False,False,False,True,8/28/15,,Secura Bio Limited,Antineoplastic agents,6/25/15,3/31/22,11.0,"Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.",,2018-06-18T12:01:00Z,2022-04-05T10:24:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/farydak
human,Trimbow,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide","beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide",4257,False,authorised,R03AL09,False,False,False,False,False,False,False,7/17/17,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases,",5/18/17,3/24/22,7.0,"Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. ",,2017-07-17T12:29:00Z,2022-04-01T14:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trimbow
human,Lenalidomide Accord,Multiple Myeloma,lenalidomide,lenalidomide,4857,False,authorised,L04AX04,False,True,False,False,False,False,False,9/20/18,,Accord Healthcare S.L.U.,Immunosuppressants,7/26/18,1/7/22,9.0,"Multiple myelomaLenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).",,2018-07-27T13:10:00Z,2022-03-31T08:40:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lenalidomide-accord
human,Bortezomib Accord,Multiple Myeloma,bortezomib,bortezomib,3984,False,authorised,L01XX32,False,True,False,False,False,False,False,7/20/15,,Accord Healthcare S.L.U.,Antineoplastic agents,5/21/15,3/25/22,13.0,"Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",,2018-05-28T14:01:00Z,2022-03-25T17:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-accord
human,Lamivudine/Zidovudine Teva,HIV Infections,"lamivudine, zidovudine","lamivudine, zidovudine",1236,False,authorised,J05AR01,False,True,False,False,False,False,False,2/28/11,,Teva Pharma B.V. ,Antivirals for systemic use,11/18/10,3/21/22,16.0,Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.,,2018-04-20T16:38:00Z,2022-03-25T11:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-zidovudine-teva
human,Zebinix,Epilepsy,eslicarbazepine acetate,eslicarbazepine acetate,988,False,authorised,N03AF04,False,False,False,False,False,False,False,4/21/09,,"BIAL - Portela & Ca, S.A.","Antiepileptics,",2/19/09,3/4/22,31.0,"Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.",,2018-05-17T12:02:00Z,2022-03-14T13:31:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix
human,Keppra,Epilepsy,levetiracetam,levetiracetam,277,False,authorised,N03AX14,False,False,False,False,False,False,False,9/29/00,,UCB Pharma SA,"Antiepileptics,",6/29/00,9/2/21,52.0,"Keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Keppra is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2018-04-26T11:28:00Z,2022-03-10T13:05:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/keppra
human,Trydonis,"Pulmonary Disease, Chronic Obstructive","beclometasone, formoterol, glycopyrronium bromide","beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium",4702,False,authorised,R03AL09,False,False,False,False,False,False,False,4/26/18,,Chiesi Farmaceutici S.p.A.,"Drugs for obstructive airway diseases,",,3/7/22,4.0,Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).,,2018-04-26T12:02:00Z,2022-03-08T13:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis
human,Jentadueto,"Diabetes Mellitus, Type 2","linagliptin, metformin hydrochloride","linagliptin, metformin",2279,False,authorised,A10BD11,False,False,False,False,False,False,False,7/19/12,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,,3/4/22,20.0,"Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.",,2018-07-20T00:00:00Z,2022-03-07T12:16:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto
human,Bortezomib Hospira,Multiple Myeloma,bortezomib,bortezomib,4207,False,authorised,L01XG01,False,True,False,False,False,False,False,7/22/16,,Pfizer Europe MA EEIG,Other antineoplastic agents,5/26/16,2/28/22,12.0,"Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",,2018-08-08T12:02:00Z,2022-03-01T11:47:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira
human,Tandemact,"Diabetes Mellitus, Type 2","pioglitazone, glimepiride","pioglitazone, glimepiride",680,False,authorised,A10BD06,False,False,False,False,False,False,False,1/8/07,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,6/24/21,20.0,Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.,,2016-11-30T01:00:00Z,2022-02-28T14:16:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact
human,Tolucombi,Hypertension,"telmisartan, hydrochlorothiazide","telmisartan, hydrochlorothiazide",2549,False,authorised,C09DA07,False,True,False,False,False,False,False,3/13/13,,"Krka, d.d., Novo mesto",telmisartan and diuretics,1/17/13,2/14/22,10.0,Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.,,2018-02-14T11:17:00Z,2022-02-25T16:55:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tolucombi
human,Zykadia,"Carcinoma, Non-Small-Cell Lung",ceritinib,ceritinib,3819,False,authorised,L01XE,False,False,False,False,False,False,False,5/6/15,,Novartis Europharm Limited,Antineoplastic agents,2/26/15,2/16/22,18.0,Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.,,2018-07-06T11:20:00Z,2022-02-25T13:05:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia
human,Inpremzia,Diabetes Mellitus,insulin human (rdna),insulin human (rdna),5331,False,authorised,A10AB01,True,False,True,False,False,False,False,4/25/22,,Baxter Holding B.V.,Drugs used in diabetes,2/24/22,,,"Inpremzia is indicated for the treatment of diabetes mellitus.,",,2022-02-23T16:15:00Z,,https://www.ema.europa.eu/en/medicines/human/EPAR/inpremzia
human,Ifirmacombi,Hypertension,"irbesartan, hydrochlorothiazide","irbesartan, hydrochlorothiazide",2302,False,authorised,C09DA04,False,True,False,False,False,False,False,3/4/11,,"Krka, d.d., Novo mesto",Agents acting on the renin-angiotensin system,,2/8/22,14.0,Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.,,2017-12-20T12:01:00Z,2022-02-09T12:05:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ifirmacombi
human,Insulin aspart Sanofi,Diabetes Mellitus,insulin aspart,insulin aspart,5033,False,authorised,A10AB05,False,False,True,False,False,False,False,6/25/20,,Sanofi Winthrop Industrie,Drugs used in diabetes,4/30/20,11/5/21,3.0,"Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.",,2020-07-07T16:54:00Z,2022-01-27T17:28:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-aspart-sanofi
human,Repaglinide Accord,"Diabetes Mellitus, Type 2",repaglinide,repaglinide,2318,False,authorised,A10BX02,False,True,False,False,False,False,False,12/22/11,,Accord Healthcare S.L.U.,Drugs used in diabetes,10/20/11,1/21/22,7.0,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",,2016-09-19T11:59:00Z,2022-01-21T13:19:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-accord
human,Atripla,HIV Infections,"efavirenz, emtricitabine, tenofovir disoproxil","efavirenz, emtricitabine, tenofovir disoproxil fumarate",797,False,withdrawn,J05AR06,False,False,False,False,False,False,False,12/13/07,,Gilead Sciences Ireland UC,Antivirals for systemic use,,8/17/21,36.0,"Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of Atripla is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Atripla.No data are currently available from clinical studies with Atripla in treatment-naive or in heavily pretreated patients.No data are available to support the combination of Atripla and other antiretroviral agents.",,2018-07-25T00:00:00Z,2022-01-21T12:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/atripla
human,Nouryant,Parkinson Disease,istradefylline,istradefylline,5308,False,refused,N04,False,False,False,False,False,False,False,,1/6/22,Kyowa Kirin Holdings B.V.,Anti-Parkinson drugs,7/22/21,,,Istradefylline is indicated in adults as an adjunctive treatment to levodopa based regimens in patients with Parkinson’s disease (PD) experiencing “OFF” time.,,2021-07-19T15:58:00Z,2022-01-19T17:38:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/nouryant
human,Lamivudine Teva Pharma B.V.,HIV Infections,lamivudine,lamivudine,1111,False,authorised,J05AF05,False,True,False,False,False,False,False,12/10/09,,Teva B.V. ,Antivirals for systemic use,,1/13/22,18.0,Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children.,,2018-04-20T00:00:00Z,2022-01-18T17:24:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva-pharma-bv
human,Azilect,Parkinson Disease,rasagiline,rasagiline,574,False,authorised,N04BD02,False,False,False,False,False,False,False,2/21/05,,Teva B.V.,Anti-Parkinson drugs,11/18/04,10/19/21,22.0,Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.,,2018-06-21T00:00:00Z,2022-01-14T14:09:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/azilect
human,Semglee,Diabetes Mellitus,insulin glargine,insulin glargine,4280,False,authorised,A10AE04,True,False,True,False,False,False,False,3/23/18,,Viatris Limited,Drugs used in diabetes,1/25/18,1/10/22,6.0,"Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",,2018-04-03T12:07:00Z,2022-01-14T12:12:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/semglee
human,Levetiracetam Accord,Epilepsy,levetiracetam,levetiracetam,2290,False,authorised,N03AX14,False,True,False,False,False,False,False,10/3/11,,Accord Healthcare S.L.U.,"Antiepileptics,",7/21/11,1/10/22,14.0,"Levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.",,2018-06-29T14:02:00Z,2022-01-13T12:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-accord
human,Pioglitazone Accord,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2277,False,authorised,A10BG03,False,True,False,False,False,False,False,3/21/12,,Accord Healthcare S.L.U.,Drugs used in diabetes,1/19/12,1/11/22,7.0,"Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2016-06-28T16:03:00Z,2022-01-13T12:29:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-accord
human,Twynsta,Hypertension,"telmisartan, amlodipine","telmisartan, amlodipine",1224,False,authorised,C09DB04,False,False,False,False,False,False,False,10/7/10,,Boehringer Ingelheim International GmbH,Agents acting on the renin-angiotensin system,,12/22/21,12.0,Treatment of essential hypertension in adults:Add-on therapyTwynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses.,,2018-05-22T00:00:00Z,2022-01-10T17:07:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/twynsta
human,Imnovid (previously Pomalidomide Celgene),Multiple Myeloma,pomalidomide,pomalidomide,2682,False,authorised,L04AX06,True,False,False,False,False,False,True,8/5/13,,Bristol-Myers Squibb Pharma EEIG,Immunosuppressants,5/30/13,12/9/21,21.0,"Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.",,2018-07-11T12:05:00Z,2022-01-10T14:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid
human,Inbrija,Parkinson Disease,levodopa,levodopa,4786,False,authorised,N04BA01,False,False,False,False,False,False,False,9/19/19,,Acorda Therapeutics Ireland Limited,Anti-Parkinson drugs,7/25/19,12/20/21,4.0,Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.,,2019-09-30T15:20:00Z,2022-01-04T17:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija
human,Trajenta,"Diabetes Mellitus, Type 2",linagliptin,linagliptin,2110,False,authorised,A10BH05,False,False,False,False,False,False,False,8/23/11,,Boehringer Ingelheim International GmbH,Drugs used in diabetes,,12/13/21,18.0,"Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.",,2018-06-26T12:52:00Z,2022-01-04T12:23:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta
human,Repaglinide Teva,"Diabetes Mellitus, Type 2",repaglinide,repaglinide,1067,False,authorised,A10BX02,False,True,False,False,False,False,False,6/28/09,,Teva Pharma B.V.,Drugs used in diabetes,4/23/09,12/13/21,9.0,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2-diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",,2016-05-25T00:00:00Z,2021-12-17T13:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-teva
human,Seebri Breezhaler,"Pulmonary Disease, Chronic Obstructive",glycopyrronium bromide,glycopyrronium bromide,2430,False,authorised,R03BB06,False,False,False,False,False,False,False,9/28/12,,Novartis Europharm Limited,"Drugs for obstructive airway diseases,",,10/28/21,12.0,Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-07-09T12:07:00Z,2021-12-15T18:40:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler
human,Apidra,Diabetes Mellitus,insulin glulisine,insulin glulisine,557,False,authorised,A10AB06,False,False,False,False,False,False,False,9/27/04,,sanofi-aventis Deutschland GmbH,Drugs used in diabetes,6/3/04,12/9/21,31.0,"Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required.",,2018-04-03T00:00:00Z,2021-12-13T18:18:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/apidra
human,Nevirapine Teva,HIV Infections,nevirapine,nevirapine,1119,False,authorised,J05AG01,False,True,False,False,False,False,False,11/30/09,,Teva B.V. ,Antivirals for systemic use,9/24/09,12/8/21,11.0,"Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.",,2016-08-28T00:00:00Z,2021-12-09T16:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/nevirapine-teva
human,Atazanavir Krka,HIV Infections,atazanavir,atazanavir (as sulfate),4859,False,authorised,J05AE08,False,True,False,False,False,False,False,3/25/19,,"Krka, d.d., Novo mesto",Antivirals for systemic use,1/31/19,11/15/21,1.0,"Atazanavir Krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).The choice of Atazanavir Krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.",,2019-05-15T10:58:00Z,2021-12-09T12:58:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/atazanavir-krka
human,Vargatef,"Carcinoma, Non-Small-Cell Lung",nintedanib,nintedanib,2569,False,authorised,L01XE3,False,False,False,False,False,False,False,11/21/14,,Boehringer Ingelheim International GmbH,Antineoplastic agents,9/25/14,11/18/21,17.0,"Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.",,2018-07-26T12:04:00Z,2021-12-07T09:55:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef
human,Lantus,Diabetes Mellitus,insulin glargine,insulin glargine,284,False,authorised,A10AE04,False,False,False,False,False,False,False,6/9/00,,sanofi-aventis Deutschland GmbH,Drugs used in diabetes,2/17/00,11/24/21,37.0,"Treatment of diabetes mellitus in adults, adolescents and children aged two years and above",,2018-04-03T14:14:00Z,2021-12-01T17:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lantus
human,Pioglitazone Teva,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2297,False,authorised,A10BG03,False,True,False,False,False,False,False,3/26/12,,Teva B.V.,Alimentary tract and metabolism,1/19/12,11/4/21,12.0,"Pioglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with- metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylureaas triple oral therapy in combination with- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2017-12-11T15:43:00Z,2021-11-24T18:45:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-teva
human,Pramipexole Teva,Parkinson Disease,pramipexole,pramipexole dihydrochloride monohydrate,940,False,authorised,N04BC05,False,True,False,False,False,False,False,12/18/08,,Teva Pharma B.V.,Anti-Parkinson drugs,10/23/08,11/5/21,22.0,"Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).",,2017-12-14T01:00:00Z,2021-11-23T18:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pramipexole-teva
human,Enurev Breezhaler,"Pulmonary Disease, Chronic Obstructive",glycopyrronium bromide,glycopyrronium bromide,2691,False,authorised,R03BB06,False,False,False,False,False,False,False,9/28/12,,Novartis Europharm Ltd,"Drugs for obstructive airway diseases,",,10/28/21,10.0,Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2017-07-13T00:00:00Z,2021-11-10T17:24:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/enurev-breezhaler
human,Zomarist,"Diabetes Mellitus, Type 2","vildagliptin, metformin","vildagliptin, metformin hydrochloride",1049,False,authorised,A10BD08,False,False,False,False,False,False,False,11/30/08,,Novartis Europharm Limited ,Drugs used in diabetes,,10/12/21,22.0,"Zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.",,2017-04-21T07:09:00Z,2021-11-10T13:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/zomarist
human,Entacapone Orion,Parkinson Disease,entacapone,entacapone,2440,False,authorised,N04BX02,False,False,False,False,False,False,False,8/18/11,,Orion Corporation,Anti-Parkinson drugs,6/23/11,10/21/21,10.0,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",,2016-12-15T10:29:00Z,2021-11-10T09:43:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-orion
human,Tovanor Breezhaler,"Pulmonary Disease, Chronic Obstructive",glycopyrronium bromide,glycopyrronium bromide,2690,False,authorised,R03BB06,False,False,False,False,False,False,False,9/28/12,,Novartis Europharm Limited,"Drugs for obstructive airway diseases,",,10/28/21,15.0,Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-07-09T15:00:00Z,2021-11-09T18:18:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tovanor-breezhaler
human,Comtess,Parkinson Disease,entacapone,entacapone,170,False,authorised,N04BX02,False,False,False,False,False,False,False,9/16/98,,Orion Corporation,Anti-Parkinson drugs,5/27/98,10/21/21,28.0,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",,2016-12-15T02:00:00Z,2021-11-05T17:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/comtess
human,Rasagiline ratiopharm,Parkinson Disease,rasagiline,rasagiline,3957,False,authorised,N04BD02,False,False,False,False,False,False,False,1/12/15,,Teva B.V.,Anti-Parkinson drugs,11/20/14,10/21/21,8.0,Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.,,2018-06-21T11:59:00Z,2021-11-05T14:31:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-ratiopharm
human,Emtricitabine/Tenofovir disoproxil Krka,HIV Infections,"emtricitabine, tenofovir disoproxil","emtricitabine, tenofovir disoproxil succinate",4215,False,authorised,J05AR03,False,True,False,False,False,False,False,12/9/16,,"KRKA, d.d., Novo mesto",Antivirals for systemic use,10/13/16,10/12/21,11.0,"Treatment of HIV-1 infectionEmtricitabine/tenofovir disoproxil Krka is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Krka is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.",,2018-07-25T12:00:00Z,2021-10-29T16:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka
human,Telmisartan Teva Pharma,Hypertension,telmisartan,telmisartan,2511,False,authorised,C09CA07,False,True,False,False,False,False,False,10/3/11,,Teva B.V.,Agents acting on the renin-angiotensin system,7/21/11,10/8/21,10.0,Treatment of essential hypertension in adults.,,2016-06-09T14:02:00Z,2021-10-26T17:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-teva-pharma
human,Xadago,Parkinson Disease,safinamide,safinamide methanesulfonate,2396,False,authorised,N04B,False,False,False,False,False,False,False,2/23/15,,Zambon SpA,Anti-Parkinson drugs,,10/11/21,12.0,Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.,,2017-12-20T13:09:00Z,2021-10-26T17:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xadago
human,Comtan,Parkinson Disease,entacapone,entacapone,171,False,authorised,N04BX02,False,False,False,False,False,False,False,9/22/98,,Orion Corporation,Anti-Parkinson drugs,,10/11/21,26.0,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",,2018-06-27T02:00:00Z,2021-10-26T16:34:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/comtan
human,Humalog,Diabetes Mellitus,insulin lispro,insulin lispro,88,False,authorised,"A10AB04, A10AD04",False,False,False,False,False,False,False,4/30/96,,Eli Lilly Nederland B.V.,Drugs used in diabetes,,9/7/21,34.0,For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.,,2018-02-01T13:43:00Z,2021-10-05T17:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/humalog
human,Entacapone Teva,Parkinson Disease,entacapone,entacapone,2075,False,authorised,N04BX02,False,True,False,False,False,False,False,2/18/11,,Teva Pharma B.V.,Anti-Parkinson drugs,11/18/10,9/10/21,10.0,"Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.",,2016-03-30T00:00:00Z,2021-09-28T17:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-teva
human,Abasaglar (previously Abasria),Diabetes Mellitus,insulin glargine,insulin glargine,2835,False,authorised,A10AE04,False,False,True,False,False,False,False,9/9/14,,Eli Lilly Nederland B.V.,Drugs used in diabetes,6/26/14,9/10/21,12.0,"Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.",,2018-02-27T14:02:00Z,2021-09-24T15:38:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/abasaglar-previously-abasria
human,Fiasp,Diabetes Mellitus,insulin aspart,insulin aspart,4046,False,authorised,A10AB05,False,False,False,False,False,False,False,1/9/17,,Novo Nordisk A/S,"Drugs used in diabetes, Insulins and analogues for injection, fast-acting",11/10/16,8/18/21,8.0,"Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.",,2018-04-12T11:59:00Z,2021-09-23T14:34:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/fiasp
human,Onbrez Breezhaler,"Pulmonary Disease, Chronic Obstructive",indacaterol,indacaterol maleate,1114,False,authorised,R03AC18,False,False,False,False,False,False,False,11/29/09,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases,",9/24/09,8/6/21,17.0,Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.,,2018-08-23T00:00:00Z,2021-09-23T12:11:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler
human,Ryzodeg,Diabetes Mellitus,"insulin degludec, insulin aspart","insulin aspart, insulin degludec",2499,False,authorised,A10AD06,False,False,False,False,False,False,False,1/21/13,,Novo Nordisk A/S,Drugs used in diabetes,10/18/12,7/15/21,13.0,"Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.",,2017-10-12T12:33:00Z,2021-09-23T11:41:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ryzodeg
human,Telmisartan Teva,Hypertension,telmisartan,telmisartan,1146,False,withdrawn,C09CA07,False,True,False,False,False,False,False,1/25/10,,Teva B.V.,Agents acting on the renin-angiotensin system,11/19/09,2/9/21,11.0,Treatment of essential hypertension in adults,,2018-07-25T00:00:00Z,2021-09-17T15:40:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-teva
human,Kirsty (previously Kixelle),Diabetes Mellitus,insulin aspart,insulin aspart,4965,False,authorised,A10AB05,True,False,True,False,False,False,False,2/5/21,,Mylan Ireland Limited,Drugs used in diabetes,12/10/20,7/16/21,1.0,"Kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.",,2021-03-16T15:47:00Z,2021-09-14T13:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/kirsty-previously-kixelle
human,Bortezomib Sun,Multiple Myeloma,bortezomib,bortezomib,4076,False,authorised,L01XG01,False,True,False,False,False,False,False,7/22/16,,SUN Pharmaceutical Industries (Europe) B.V.,Antineoplastic agents,3/26/16,8/31/21,12.0,"Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",,2017-09-07T14:03:00Z,2021-09-09T11:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-sun
human,Oslif Breezhaler,"Pulmonary Disease, Chronic Obstructive",indacaterol,indacaterol maleate,1210,False,authorised,R03AC18,False,False,False,False,False,False,False,11/29/09,,Novartis Europharm Limited ,"Drugs for obstructive airway diseases,",,8/6/21,17.0,Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.,,2018-05-08T01:00:00Z,2021-09-08T13:48:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/oslif-breezhaler
human,Hirobriz Breezhaler,"Pulmonary Disease, Chronic Obstructive",indacaterol,indacaterol maleate,1211,False,authorised,R03AC18,False,False,False,False,False,False,False,11/30/09,,Novartis Europharm Limited,"Drugs for obstructive airway diseases,",9/24/09,8/6/21,18.0,Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.,,2018-08-23T13:40:00Z,2021-09-08T13:39:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/hirobriz-breezhaler
human,Xoterna Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide","indacaterol, glycopyrronium bromide",3755,False,authorised,R03AL04,False,False,False,False,False,False,False,9/18/13,,Novartis Europharm Limited,Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids,7/25/13,8/6/21,16.0,Xoterna Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-07-23T12:32:00Z,2021-09-07T16:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xoterna-breezhaler
human,Irbesartan Teva,Hypertension,irbesartan,irbesartan,1093,False,authorised,C09CA04,False,True,False,False,False,False,False,10/30/09,,Teva B.V.,Agents acting on the renin-angiotensin system,7/23/09,7/29/21,15.0,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,,2016-08-31T00:00:00Z,2021-09-06T16:46:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva
human,Ultibro Breezhaler,"Pulmonary Disease, Chronic Obstructive","indacaterol, glycopyrronium bromide","indacaterol, glycopyrronium bromide",2679,False,authorised,R03AL04,False,False,False,False,False,False,False,9/19/13,,Novartis Europharm Limited,"Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids, Drugs for obstructive airway diseases,",,8/6/21,13.0,Ultibro Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).,,2018-07-23T17:15:00Z,2021-09-01T13:07:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ultibro-breezhaler
human,Bortezomib Fresenius Kabi,Multiple Myeloma,bortezomib,bortezomib,5074,False,authorised,L01XG01,False,True,False,False,False,False,False,11/14/19,,Fresenius Kabi Deutschland GmbH,Antineoplastic agents,9/19/19,7/28/21,5.0,"Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",,2019-11-25T15:01:00Z,2021-09-01T12:33:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-fresenius-kabi
human,Ifirmasta (previously Irbesartan Krka),Hypertension,irbesartan,irbesartan hydrochloride,962,False,authorised,C09CA04,False,True,False,False,False,False,False,12/1/08,,"Krka, d.d., Novo mesto",Agents acting on the renin-angiotensin system,9/25/08,6/30/21,14.0,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,,2016-10-05T14:13:00Z,2021-08-03T17:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ifirmasta
human,Portrazza,"Carcinoma, Non-Small-Cell Lung",necitumumab,necitumumab,3886,False,withdrawn,L01,True,False,False,False,False,False,False,2/15/16,,Eli Lilly Nederland B.V.,Antineoplastic agents,,2/18/21,3.0,Portrazza in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.,,2016-11-10T12:58:00Z,2021-07-27T13:54:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/portrazza
human,Emtricitabine/Tenofovir disoproxil Zentiva,HIV Infections,"emtricitabine, tenofovir disoproxil","emtricitabine, tenofovir disoproxil phosphate",4137,False,authorised,J05AR03,False,True,False,False,False,False,False,11/9/16,,Zentiva k.s.,Antivirals for systemic use,9/15/16,7/16/21,6.0,"Treatment of HIV-1 infectionEmtricitabine/Tenofovir disoproxil Zentiva is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents.Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.",,2017-10-13T12:11:00Z,2021-07-21T13:24:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-zentiva
human,Vizimpro,"Carcinoma, Non-Small-Cell Lung",dacomitinib,dacomitinib monohydrate,4779,False,authorised,L01EB07,True,False,False,False,False,False,False,4/2/19,,Pfizer Europe MA EEIG,Antineoplastic agents,1/31/19,7/2/21,2.0,"Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.",,2019-06-05T17:19:00Z,2021-07-21T12:27:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro
human,Competact,"Diabetes Mellitus, Type 2","pioglitazone, metformin","pioglitazone, metformin hydrochloride",655,False,authorised,A10BD05,False,False,False,False,False,False,False,7/28/06,,CHEPLAPHARM Arzneimittel GmbH,Drugs used in diabetes,,6/21/21,20.0,"Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.",,2016-12-12T01:00:00Z,2021-07-20T16:21:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/competact
human,Levemir,Diabetes Mellitus,insulin detemir,insulin detemir,528,False,authorised,A10AE05,False,False,False,False,False,False,False,6/1/04,,Novo Nordisk A/S,Drugs used in diabetes,2/26/04,4/9/21,29.0,"Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.",,2018-04-09T00:00:00Z,2021-07-13T14:47:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/levemir
human,Ribavirin Teva Pharma B.V.,"Hepatitis C, Chronic",ribavirin,ribavirin,1064,False,withdrawn,J05AP01,False,True,False,False,False,False,False,7/1/09,,Teva B.V.,Antivirals for systemic use,4/23/09,6/22/21,14.0,"Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).",,2016-11-04T01:00:00Z,2021-07-09T14:05:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-teva-pharma-bv
human,Ribavirin Teva,"Hepatitis C, Chronic",ribavirin,ribavirin,1018,False,withdrawn,J05AB04,False,True,False,False,False,False,False,3/31/09,,Teva B.V.,Antivirals for systemic use,,6/22/21,15.0,"Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.",,2016-11-14T01:00:00Z,2021-07-09T14:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-teva
human,Baqsimi,Diabetes Mellitus,glucagon,glucagon,3848,False,authorised,H04AA01,False,False,False,False,False,False,False,12/16/19,,Eli Lilly Nederland B.V.,"Pancreatic hormones, Glycogenolytic hormones",,6/18/21,1.0,"Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.",,2020-02-06T15:50:00Z,2021-07-05T17:29:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/baqsimi
human,Trulicity,"Diabetes Mellitus, Type 2",dulaglutide,dulaglutide,2825,False,authorised,A10BJ05,False,False,False,False,False,False,False,11/21/14,,Eli Lilly Nederland B.V.,"Drugs used in diabetes, Blood glucose lowering drugs, excl. insulins",9/25/14,6/17/21,16.0,"Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.",,2018-07-02T12:04:00Z,2021-07-05T16:18:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity
human,Lyumjev (previously Liumjev),Diabetes Mellitus,insulin lispro,insulin lispro,5037,False,authorised,A10AB04,True,False,False,False,False,False,False,3/24/20,,Eli Lilly Nederland B.V.,Drugs used in diabetes,1/30/20,6/9/21,4.0,Treatment of diabetes mellitus in adults.,,2020-04-16T16:56:00Z,2021-07-02T08:46:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lyumjev-previously-liumjev
human,Velcade,Multiple Myeloma,bortezomib,bortezomib,539,False,authorised,L01XG01,False,False,False,False,False,False,False,4/26/04,,Janssen-Cilag International NV,Antineoplastic agents,,5/13/21,45.0,"Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation.Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.",,2017-02-21T02:00:00Z,2021-06-04T16:08:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/velcade
human,PegIntron,"Hepatitis C, Chronic",peginterferon alfa-2b,peginterferon alfa-2b,280,False,withdrawn,L03AB10,False,False,False,False,False,False,False,5/24/00,,Merck Sharp & Dohme B.V.,"Immunostimulants,",,4/21/21,36.0,"Adults (tritherapy)PegIntron in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-C (CHC) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.Please refer to the ribavirin and boceprevir summaries of product characteristics (SmPCs) when PegIntron is to be used in combination with these medicines.Adults (bitherapy and monotherapy)PegIntron is indicated for the treatment of adult patients (18 years of age and older) with CHC who are positive for hepatitis-C-virus RNA (HCV-RNA), including patients with compensated cirrhosis and / or co-infected with clinically stable HIV.PegIntron in combination with ribavirin (bitherapy) is indicated for the treatment of CHC infection in adult patients who are previously untreated including patients with clinically stable HIV co-infection and in adult patients who have failed previous treatment with interferon-alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon-alpha monotherapy.Interferon monotherapy, including PegIntron, is indicated mainly in case of intolerance or contraindication to ribavirin.Please refer to the ribavirin SmPC when PegIntron is to be used in combination with ribavirin.Paediatric population (bitherapy)PegIntron is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents who have CHC, previously untreated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The decision to treat should be made on a case-by-case basis.Please refer to the ribavirin SmPC for capsules or oral solution when PegIntron is to be used in combination with ribavirin.",,2017-06-22T00:00:00Z,2021-06-03T14:52:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pegintron
human,Pioglitazone Actavis,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2324,False,authorised,A10BG03,False,True,False,False,False,False,False,3/15/12,,Actavis Group PTC ehf  ,Drugs used in diabetes,1/19/12,4/26/21,8.0,"Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin.a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).",,2018-03-20T13:00:00Z,2021-05-27T11:56:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-actavis
human,Victoza,"Diabetes Mellitus, Type 2",liraglutide,liraglutide,1026,False,authorised,A10BJ02,False,False,False,False,False,False,False,6/30/09,,Novo Nordisk A/S,Drugs used in diabetes,4/23/09,9/24/20,22.0,"Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.",,2017-09-22T00:00:00Z,2021-04-29T11:21:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/victoza
human,Giotrif,"Carcinoma, Non-Small-Cell Lung",afatinib,afatinib,2280,False,authorised,L01XE13,False,False,False,False,False,False,False,9/25/13,,Boehringer Ingelheim International GmbH,Antineoplastic agents,7/25/13,4/6/21,14.0,Giotrif as monotherapy is indicated for the treatment ofEpidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.,,2018-06-28T12:32:00Z,2021-04-21T17:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif
human,Edarbi,Hypertension,azilsartan medoxomil,azilsartan medoxomil,2293,False,authorised,C09CA09,False,False,False,False,False,False,False,12/7/11,,Takeda Pharma A/S,Agents acting on the renin-angiotensin system,9/22/11,1/19/21,9.0,Edarbi is indicated for the treatment of essential hypertension in adults.,,2018-03-20T15:40:00Z,2021-02-10T18:18:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi
human,ViraferonPeg,"Hepatitis C, Chronic",peginterferon alfa-2b,peginterferon alfa-2b,329,False,withdrawn,L03AB10,False,False,False,False,False,False,False,5/28/00,,Merck Sharp  Dohme Ltd ,"Immunostimulants,",2/17/00,9/27/18,36.0,"Adults (tritherapy)ViraferonPeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic-hepatitis-C (CHC) genotype-1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.Please refer to the ribavirin and boceprevir summaries of product characteristics (SmPCs) when ViraferonPeg is to be used in combination with these medicines.Adults (bitherapy and monotherapy)ViraferonPeg is indicated for the treatment of adult patients (18 years of age and older) with CHC who are positive for hepatitis-C-virus RNA (HCV-RNA), including patients with compensated cirrhosis and / or co-infected with clinically stable HIV.ViraferonPeg in combination with ribavirin (bitherapy) is indicated for the treatment of CHC infection in adult patients who are previously untreated including patients with clinically stable HIV co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy.Interferon monotherapy, including ViraferonPeg, is indicated mainly in case of intolerance or contraindication to ribavirin.Please refer to the ribavirin SmPC when ViraferonPeg is to be used in combination with ribavirin.Paediatric population (bitherapy)ViraferonPeg is indicated in a combination regimen with ribavirin for the treatment of children three years of age and older and adolescents, who have chronic hepatitis C, previously untreated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The decision to treat should be made on a case-by-case basis.Please refer to the ribavirin SmPC for capsules or oral solution when ViraferonPeg is to be used in combination with ribavirin.",,2017-06-22T15:33:00Z,2021-01-22T13:15:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/viraferonpeg
human,Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG),Hypertension,telmisartan,telmisartan,211,False,authorised,C09CA07,False,False,False,False,False,False,False,12/16/98,,Bayer AG,Agents acting on the renin-angiotensin system,7/23/98,11/26/20,30.0,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.",,2018-04-04T00:00:00Z,2020-12-18T12:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg
human,Pritor,Hypertension,telmisartan,telmisartan,210,False,authorised,C09CA07,False,False,False,False,False,False,False,12/11/98,,Bayer AG,Agents acting on the renin-angiotensin system,7/23/98,11/26/20,29.0,"HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.",,2018-04-13T00:00:00Z,2020-12-10T19:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pritor
human,Insulatard,Diabetes Mellitus,insulin human (rdna),insulin human,441,False,authorised,A10AC01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,,9/24/20,20.0,Treatment of diabetes mellitus.,,2018-04-26T02:00:00Z,2020-11-23T14:25:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/insulatard
human,NovoRapid,Diabetes Mellitus,insulin aspart,insulin aspart,258,False,authorised,A10AB05,False,False,False,False,False,False,False,9/7/99,,Novo Nordisk A/S,Drugs used in diabetes,5/20/99,9/24/20,31.0,"NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.",,2018-04-26T00:00:00Z,2020-11-23T13:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/novorapid
human,Ribavirin Mylan (previously Ribavirin Three Rivers),"Hepatitis C, Chronic",ribavirin,ribavirin,1185,False,withdrawn,J05AB04,False,True,False,False,False,False,False,6/10/10,,Mylan S.A.S,Antivirals for systemic use,,3/13/19,10.0,"Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.Naïve patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.Children and adolescentsRibavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).Previously treatment-failure patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.",,2016-07-29T00:00:00Z,2020-11-23T12:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-mylan
human,NovoMix,Diabetes Mellitus,insulin aspart,insulin aspart,308,False,authorised,A10AD05,False,False,False,False,False,False,False,8/1/00,,Novo Nordisk A/S,Drugs used in diabetes,4/13/00,9/24/20,28.0,Treatment of diabetes mellitus.,,2018-04-11T15:00:00Z,2020-11-12T11:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/novomix
human,Protaphane,Diabetes Mellitus,insulin human (rdna),insulin human,442,False,authorised,A10AC01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,4/25/02,9/24/20,18.0,Treatment of diabetes mellitus.,,2018-04-26T00:00:00Z,2020-10-27T19:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/protaphane
human,Actrapid,Diabetes Mellitus,human insulin (rdna),human insulin,424,False,authorised,A10AB01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,,9/24/20,17.0,Treatment of diabetes mellitus.,,2018-03-14T01:00:00Z,2020-10-21T09:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/actrapid
human,Actraphane,Diabetes Mellitus,insulin human (rdna),insulin human,427,False,authorised,A10AD01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,4/25/02,9/24/20,19.0,Treatment of diabetes mellitus.,,2018-04-26T00:00:00Z,2020-10-15T11:42:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/actraphane
human,Zerit,HIV Infections,stavudine,stavudine,110,False,withdrawn,J05AF04,False,False,False,False,False,False,False,5/8/96,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,,2/13/19,31.0,Hard capsulesZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.Powder for oral solutionZerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.,,2006-08-11T12:00:00Z,2020-10-13T14:56:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/zerit
human,Xultophy,"Diabetes Mellitus, Type 2","insulin degludec, liraglutide","insulin degludec, liraglutide",2647,False,authorised,A10,False,False,False,False,False,False,False,9/18/14,,Novo Nordisk A/S,Drugs used in diabetes,7/25/14,9/24/20,15.0,Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control.,,2018-06-07T12:06:00Z,2020-10-13T14:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy
human,Mixtard,Diabetes Mellitus,insulin human (rdna),insulin human,428,False,authorised,A10AD01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,4/25/02,9/24/20,19.0,Treatment of diabetes mellitus.,,2018-04-26T00:00:00Z,2020-10-12T16:09:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/mixtard
human,Qtrilmet,"Diabetes Mellitus, Type 2","metformin hydrochloride, saxagliptin, dapagliflozin","metformin hydrochloride, saxagliptin, dapagliflozin",4910,False,withdrawn,A10BD,False,False,False,False,False,False,False,11/11/19,,AstraZeneca AB,Drugs used in diabetes,9/19/19,8/14/20,2.0,Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.when already being treated with metformin and saxagliptin and dapagliflozin.,,2019-12-10T11:56:00Z,2020-10-09T15:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet
human,Daklinza,"Hepatitis C, Chronic",daclatasvir,daclatasvir dihydrochloride,3768,False,withdrawn,J05AP07,False,False,False,False,False,True,False,8/22/14,,Bristol-Myers Squibb Pharma EEIG,Antivirals for systemic use,6/26/14,7/24/19,15.0,"Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults (see sections 4.2, 4.4 and 5.1)., , For HCV genotype specific activity, see sections 4.4 and 5.1.,",,2018-06-14T13:38:00Z,2019-08-30T09:58:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/daklinza
human,Eperzan,"Diabetes Mellitus, Type 2",albiglutide,albiglutide,2735,False,withdrawn,A10BJ04,False,False,False,False,False,False,False,3/20/14,,GlaxoSmithKline Trading Services Limited,Drugs used in diabetes,1/22/14,9/14/17,8.0,"Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:MonotherapyWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.Add-on combination therapyIn combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).",,2017-09-14T12:04:00Z,2019-02-20T11:55:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan
human,Lusduna,Diabetes Mellitus,insulin glargine,insulin glargine,4101,False,withdrawn,A10AE04,False,False,True,False,False,False,False,1/3/17,,Merck Sharp & Dohme B.V.,Drugs used in diabetes,11/9/16,10/29/18,2.0,"Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.,",,2018-06-15T11:59:00Z,2019-01-22T15:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/lusduna
human,Trobalt,Epilepsy,retigabine,retigabine,1245,False,withdrawn,N03AX21,False,False,False,False,False,False,False,3/27/11,,Glaxo Group Limited ,"Antiepileptics,",,7/19/18,12.0,"Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.",,2016-05-11T00:00:00Z,2018-11-19T17:20:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt
human,Numient,Parkinson Disease,"levodopa, carbidopa","levodopa, carbidopa",2611,False,withdrawn,N04BA02,False,False,False,False,False,False,False,11/19/15,,Amneal Pharma Europe Ltd,Anti-Parkinson drugs,9/24/15,8/3/18,3.0,Symptomatic treatment of adult patients with Parkinson’s disease,,2018-08-03T12:09:00Z,2018-08-09T09:25:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/numient
human,Victrelis,"Hepatitis C, Chronic",boceprevir,boceprevir,2332,False,withdrawn,J05AE,False,False,False,False,False,False,False,7/18/11,,Merck Sharp  Dohme Ltd,Antivirals for systemic use,,6/29/17,22.0,"Victrelis is indicated for the treatment of chronic hepatitis-C (CHC) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.",,2017-06-29T00:00:00Z,2018-07-31T17:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/victrelis
human,Olysio,"Hepatitis C, Chronic",simeprevir,simeprevir,2777,False,withdrawn,J05AE14,True,False,False,False,False,False,False,5/14/14,,Janssen-Cilag International NV,Antivirals for systemic use,3/20/14,2/8/18,13.0,Olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.For hepatitis C virus (HCV) genotype specific activity.,,2018-02-08T01:00:00Z,2018-05-23T11:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/olysio
human,Prandin,"Diabetes Mellitus, Type 2",repaglinide,repaglinide,362,False,authorised,A10BX02,False,False,False,False,False,False,False,1/29/01,,Novo Nordisk A/S,Drugs used in diabetes,,9/6/17,16.0,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",,2017-09-06T00:00:00Z,2018-05-14T14:36:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/prandin
human,Insulin Human Winthrop,Diabetes Mellitus,insulin human,insulin human,761,False,withdrawn,A10AB01,False,False,False,False,False,False,False,1/17/07,,sanofi-aventis Deutschland GmbH,Drugs used in diabetes,,4/28/16,15.0,"Diabetes mellitus where treatment with insulin is required. Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.",,2016-04-28T00:00:00Z,2018-04-30T16:51:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-human-winthrop
human,Libertek,"Pulmonary Disease, Chronic Obstructive",roflumilast,roflumilast,2399,False,withdrawn,R03DX08,False,False,False,False,False,False,False,2/28/11,,AstraZeneca AB,"Drugs for obstructive airway diseases,",,1/11/18,11.0,Libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,,2018-01-11T12:01:19Z,2018-02-08T12:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/libertek
human,Daliresp,"Pulmonary Disease, Chronic Obstructive",roflumilast,roflumilast,2398,False,withdrawn,R03DX07,False,False,False,False,False,False,False,2/28/11,,AstraZeneca AB,"Drugs for obstructive airway diseases,",,11/3/16,9.0,Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,,2016-11-03T01:00:00Z,2018-02-06T18:32:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/daliresp
human,NovoNorm,"Diabetes Mellitus, Type 2",repaglinide,repaglinide,187,False,authorised,A10BX02,False,False,False,False,False,False,False,8/16/98,,Novo Nordisk A/S,Drugs used in diabetes,,9/5/17,16.0,"Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in type 2 diabetes patients who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.",,2017-09-06T00:00:00Z,2017-09-28T17:22:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/novonorm
human,Sabervel,Hypertension,irbesartan,irbesartan,2510,False,withdrawn,C09CA04,False,True,False,False,False,False,False,4/13/12,,Pharmathen S.A.,Agents acting on the renin-angiotensin system,,9/4/14,2.0,Sabervel is indicated in adults for the treatment of essential hypertension.It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.,,2014-09-04T14:09:00Z,2017-06-29T16:30:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sabervel
human,Vitekta,HIV Infections,elvitegravir,elvitegravir,2577,False,withdrawn,J05AX11,True,False,False,False,False,False,False,11/13/13,,Gilead Sciences International Ltd,Antivirals for systemic use,9/19/13,11/3/16,4.0,"Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.",,2016-11-03T13:08:30Z,2017-05-29T13:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/vitekta
human,Imprida,Hypertension,"amlodipine, valsartan","valsartan, amlodipine (as amlodipine besilate)",775,False,withdrawn,C09DB01,False,False,False,False,False,False,False,1/17/07,,Novartis Europharm Ltd,Agents acting on the renin-angiotensin system,,4/3/17,20.0,Treatment of essential hypertension.Imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.,,2017-04-03T00:00:00Z,2017-05-11T12:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/imprida
human,Dutrebis,HIV Infections,"lamivudine, raltegravir potassium","lamivudine, raltegravir potassium",3823,False,withdrawn,J05AR16,False,False,False,False,False,False,False,3/26/15,,Merck Sharp  Dohme Limited,"Antivirals for systemic use, Antivirals for treatment of HIV infections, combinations",,3/26/15,0.0,"Dutrebis is indicated in combination with other anti‑retroviral medicinal products for the treatment of human immunodeficiency virus (HIV‑1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1).",,2015-03-26T13:10:00Z,2017-04-27T16:25:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/dutrebis
human,Rasilamlo,Hypertension,"aliskiren hemifumarate, amlodipine besilate","aliskiren, amlodipine",2073,False,withdrawn,C09XA53,False,False,False,False,False,False,False,4/14/11,,Novartis Europharm Ltd,Agents acting on the renin-angiotensin system,,6/25/15,7.0,Rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.,,2015-06-25T12:26:00Z,2017-03-28T11:35:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rasilamlo
human,Incivo,"Hepatitis C, Chronic",telaprevir,telaprevir,2313,False,withdrawn,J05AE,True,False,False,False,False,False,False,9/19/11,,Janssen-Cilag International N.V.,Antivirals for systemic use,,6/25/15,19.0,"Incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.",,2015-06-25T16:03:27Z,2016-10-06T14:04:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/incivo
human,Avandamet,"Diabetes Mellitus, Type 2","rosiglitazone, metformin","rosiglitazone, metformin hydrochloride",522,False,withdrawn,A10BD03,False,False,False,False,False,False,False,10/20/03,,SmithKline Beecham Plc,Drugs used in diabetes,,12/3/10,16.0,"AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).",,2010-12-03T02:00:00Z,2016-06-08T15:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/avandamet
human,Avandia,"Diabetes Mellitus, Type 2",rosiglitazone,rosiglitazone,268,False,withdrawn,A10BG02,False,False,False,False,False,False,False,7/11/00,,SmithKline Beecham Plc,Drugs used in diabetes,,12/3/10,23.0,"Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy-in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with-metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin-a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylureaas triple oral therapy in combination with-metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy (see section 4.4).",,2010-12-03T01:00:00Z,2016-06-08T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/avandia
human,Paglitaz,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2309,False,withdrawn,A10BG03,False,True,False,False,False,False,False,3/21/12,,"Krka, d.d., Novo mesto",Drugs used in diabetes,,1/15/14,1.0,"Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2014-01-15T15:02:42Z,2016-03-10T12:06:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/paglitaz
human,Solumarv,Diabetes Mellitus,insulin human,insulin human,3858,False,refused,A10AB01,False,False,True,False,False,False,False,,2/11/16,Marvel Lifesciences Ltd,,11/19/15,2/11/16,0.0,Treatment of diabetes,,2016-02-11T13:01:00Z,2016-02-16T11:15:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/solumarv-0
human,Nivolumab BMS,"Carcinoma, Non-Small-Cell Lung",nivolumab,nivolumab,3840,False,withdrawn,L01XC17,False,False,False,False,False,False,False,7/20/15,,Bristol-Myers Squibb Pharma EEIG,"Antineoplastic and immunomodulating agents, Monoclonal antibodies,",5/21/15,11/30/15,0.0,Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.,,2015-11-30T13:01:20Z,2016-01-14T17:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/nivolumab-bms
human,Ipreziv,Hypertension,azilsartan medoxomil,azilsartan medoxomil,2517,False,withdrawn,C09CA09,True,False,False,False,False,False,False,12/7/11,,Takeda Pharma A/S,Agents acting on the renin-angiotensin system,,10/27/14,4.0,Ipreziv is indicated for the treatment of essential hypertension in adults.,,2014-10-27T13:00:00Z,2014-12-19T18:15:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ipreziv
human,Pioglitazone Krka,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2453,False,withdrawn,A10BG03,False,True,False,False,False,False,False,3/21/12,,"Krka, d.d., Novo mesto",Drugs used in diabetes,,9/16/14,2.0,"Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea; Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.",,2014-09-16T14:02:40Z,2014-09-26T17:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/pioglitazone-krka
human,Viracept,HIV Infections,nelfinavir,nelfinavir,164,False,withdrawn,J05AE04,False,False,False,False,False,False,False,1/22/98,,Roche Registration Ltd.,Antivirals for systemic use,,1/23/13,25.0,"Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.",,2013-01-23T01:00:00Z,2014-06-10T17:50:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/viracept
human,Onduarp,Hypertension,"telmisartan, amlodipine",telmisartan,2118,False,withdrawn,C09DB04,False,False,False,False,False,False,False,11/24/11,,Boehringer Ingelheim International GmbH,Cardiovascular system,,2/17/14,2.0,Treatment of essential hypertension in adults:Add on therapyOnduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Onduarp containing the same component doses.,,2014-02-17T15:11:00Z,2014-04-02T15:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/onduarp
human,Sepioglin,"Diabetes Mellitus, Type 2",pioglitazone,pioglitazone hydrochloride,2021,False,withdrawn,A10BG03,False,True,False,False,False,False,False,3/9/12,,Vaia S.A.,Drugs used in diabetes,,6/6/13,1.0,"Pioglitazone is indicated as second- or third-line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. Pioglitazone is also indicated for combination with insulin in type-2-diabetes-mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).",,2013-06-06T00:00:00Z,2013-07-18T13:45:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sepioglin
human,Ribavirin BioPartners,"Hepatitis C, Chronic",ribavirin,ribavirin,1184,False,withdrawn,J05AB04,False,True,False,False,False,False,False,4/6/10,,BioPartners GmbH,Antivirals for systemic use,,11/21/12,2.0,"Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4)Children three years of age and older and adolescentsRibavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).Previous-treatment-failure patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).",,2012-11-21T01:00:00Z,2013-05-06T10:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ribavirin-biopartners
human,Riprazo,Hypertension,aliskiren,aliskiren,853,False,withdrawn,C09XA02,False,False,False,False,False,False,False,8/22/07,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,8/17/12,8.0,Treatment of essential hypertension.,,2012-08-17T00:00:00Z,2013-03-01T16:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/riprazo
human,Imprida HCT,Hypertension,"amlodipine, valsartan, hydrochlorothiazide","amlodipine, valsartan, hydrochlorothiazide",1161,False,withdrawn,C09DX01,False,False,False,False,False,False,False,10/15/09,,Novartis Europharm Ltd.,"Angiotensin II antagonists, plain, Angiotensin II antagonists, combinations",,10/20/12,3.0,"Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.",,2012-10-20T00:00:00Z,2012-10-22T09:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/imprida-hct
human,Rasitrio,Hypertension,"aliskiren, amlodipine, hydrochlorothiazide","aliskiren, amlodipine, hydrochlorothiazide",2017,False,withdrawn,C09XA54,False,False,False,False,False,False,False,11/22/11,,Novartis Europharm Ltd.,Cardiovascular system,,10/3/13,1.0,"Rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.",,2013-10-03T15:30:00Z,2012-09-20T18:37:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/rasitrio
human,Riprazo HCT,Hypertension,"aliskiren, hydrochlorothiazide","aliskiren, hydrochlorothiazide",2420,False,withdrawn,C09XA52,False,False,False,False,False,False,False,4/13/11,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,8/30/12,0.0,"Treatment of essential hypertension in adults.Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",,2012-08-30T11:21:00Z,2012-09-20T11:59:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/riprazo-hct
human,Sprimeo HCT,Hypertension,"aliskiren, hydrochlorothiazide","aliskiren, hydrochlorothiazide",2421,False,withdrawn,C09XA52,False,False,False,False,False,False,False,6/23/11,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,7/6/12,0.0,"Treatment of essential hypertension in adults.Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.",,2012-07-06T00:00:00Z,2012-08-28T17:04:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sprimeo-hct
human,Exalief,Epilepsy,eslicarbazepine acetate,eslicarbazepine acetate,987,False,withdrawn,N03AF04,False,False,False,False,False,False,False,4/21/09,,"BIAL - Portela  Ca, S.A.","Antiepileptics,",,4/21/12,5.0,Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.,,2012-04-21T00:00:00Z,2012-08-16T15:10:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/exalief
human,Sprimeo,Hypertension,aliskiren,aliskiren,851,False,withdrawn,C09XA02,False,False,False,False,False,False,False,8/22/07,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,7/4/12,5.0,Treatment of essential hypertension.,,2012-07-04T00:00:00Z,2012-07-23T17:03:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/sprimeo
human,Avaglim,"Diabetes Mellitus, Type 2","rosiglitazone, glimepiride","rosiglitazone, glimepiride",675,False,withdrawn,A10BD04,False,False,False,False,False,False,False,6/27/06,,SmithKline Beecham Ltd,Drugs used in diabetes,,7/26/11,11.0,"AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.",,2011-07-26T00:00:00Z,2011-08-12T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/avaglim
human,Agenerase,HIV Infections,amprenavir,amprenavir,264,False,withdrawn,J05AE05,False,False,False,False,False,False,False,10/20/00,,Glaxo Group Ltd.,Antivirals for systemic use,,4/29/11,18.0,"Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years. Agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). The choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).The benefit of Agenerase boosted with ritonavir has not been demonstrated in PI nave patients (see section 5.1)",,2011-04-29T00:00:00Z,2011-06-21T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/agenerase
human,Enviage,Hypertension,aliskiren,aliskiren,850,False,withdrawn,C09XA02,False,False,False,False,False,False,False,8/22/07,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,4/22/09,4.0,Treatment of essential hypertension,,2009-04-22T00:00:00Z,2011-05-19T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/enviage
human,Irbesartan BMS,Hypertension,irbesartan,irbesartan,786,False,withdrawn,C09CA04,False,False,False,False,False,False,False,1/19/07,,Bristol-Myers Squibb Pharma EEIG,Agents acting on the renin-angiotensin system,,4/7/09,7.0,Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see section 5.1).,,2009-04-07T02:00:00Z,2009-11-26T02:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-bms
human,Irbesartan Hydrochlorothiazide BMS,Hypertension,"irbesartan, hydrochlorothiazide","irbesartan, hydrochlorothiazide",784,False,withdrawn,C09DA04,False,False,False,False,False,False,False,1/19/07,,Bristol-Myers Squibb Pharma EEIG,Agents acting on the renin-angiotensin system,,10/9/09,8.0,Treatment of essential hypertension.This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).,,2009-10-09T00:00:00Z,2009-11-24T01:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-bms
human,Tekturna,Hypertension,aliskiren,aliskiren,852,False,withdrawn,C09XA02,False,False,False,False,False,False,False,8/22/07,,Novartis Europharm Ltd.,Agents acting on the renin-angiotensin system,,4/22/09,4.0,Treatment of essential hypertension,,2009-04-22T02:09:00Z,2009-09-25T02:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/tekturna
human,Trazec,"Diabetes Mellitus, Type 2",nateglinide,nateglinide,383,False,withdrawn,A10BX03,False,False,False,False,False,False,False,4/3/01,,Novartis Europharm Ltd.,Drugs used in diabetes,,7/23/07,5.0,Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.,,2007-07-23T00:00:00Z,2009-08-24T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/trazec
human,Velosulin,Diabetes Mellitus,insulin human (rdna),insulin human,423,False,withdrawn,A10AB01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,,3/17/08,5.0,Treatment of diabetes mellitus.,,2008-03-17T00:09:21Z,2009-04-17T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/velosulin
human,Exubera,Diabetes Mellitus,insulin human,insulin human,588,False,withdrawn,A10AF01,False,False,False,False,False,False,False,1/24/06,,Pfizer Limited,Drugs used in diabetes,,7/9/08,6.0,"EXUBERA is indicated for the treatment of adult patients with type 2 diabetes mellitus notadequately controlled with oral antidiabetic agents and requiring insulin therapy.EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, inaddition to long or intermediate acting subcutaneous insulin, for whom the potential benefits ofadding inhaled insulin outweigh the potential safety concerns (see section 4.4).",,2008-07-09T02:09:21Z,2008-11-16T02:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/exubera
human,Monotard,Diabetes Mellitus,insulin human (rdna),insulin human,440,False,withdrawn,A10AC01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,,4/25/02,0.0,Treatment of diabetes mellitus.,,2002-04-25T00:09:21Z,2008-02-14T01:09:21Z,https://www.ema.europa.eu/en/medicines/human/EPAR/monotard
human,Ultratard,Diabetes Mellitus,insulin human (rdna),insulin human,439,False,withdrawn,A10AE01,False,False,False,False,False,False,False,10/7/02,,Novo Nordisk A/S,Drugs used in diabetes,,10/7/02,0.0,Treatment of diabetes mellitus.,,2002-10-07T00:09:21Z,2008-02-14T01:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/ultratard
human,Fortovase,HIV Infections,saquinavir,saquinavir,178,False,withdrawn,J05AE01,False,False,False,False,False,False,False,8/20/98,,Roche Registration Ltd.,Antivirals for systemic use,,8/20/98,11.0,Fortovase is indicated for treatment of HIV-1 infected adult patients. Fortovase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2).,,1998-08-20T00:00:00Z,2006-08-07T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/fortovase
human,Alpheon,"Hepatitis C, Chronic",interferon alfa-2a,recombinant human interferon alfa-2a,585,False,refused,L03AB04,False,False,True,False,False,False,False,,9/5/06,BioPartners GmbH,"Immunostimulants,",6/28/06,6/28/06,0.0,Adult patients with histologically proven chronic hepatitis C who are positive for hepatitis C virus (HCV) antibodies or HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation.The efficacy of Interferon alfa-2a in the treatment of hepatitis C is enhanced when combined with ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.,,2006-06-28T00:09:00Z,2006-06-28T00:09:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/alpheon
human,Infergen,"Hepatitis C, Chronic",interferon alfacon-1,interferon alfacon-1,186,False,withdrawn,L03AB09,False,False,False,False,False,False,False,2/1/99,,Astellas Pharma Europe B.V.,"Immunostimulants,",,5/5/06,8.0,Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C.Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to ribavirin.,,2006-05-05T00:00:00Z,2006-06-01T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/infergen
human,Daquiran,Parkinson Disease,pramipexole,pramipexole dihydrochloride monohydrate,135,False,withdrawn,N04BC05,False,False,False,False,False,False,False,10/27/97,,Dr. Karl Thomae GmbH,Anti-Parkinson drugs,,2/2/06,5.0,"DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).",,2006-02-02T01:00:00Z,2006-05-23T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/daquiran
human,Venvia,"Diabetes Mellitus, Type 2",rosiglitazone,rosiglitazone,270,False,withdrawn,A10BG02,False,False,False,False,False,False,False,7/11/00,,SmithKline Beecham Plc,Drugs used in diabetes,,11/25/04,6.0,"Rosiglitazone is indicated as oral monotherapy in type 2 diabetes mellitus patients, particularly overweight patients, inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.Rosiglitazone is also indicated for oral combination treatment in type 2 diabetes mellitus patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea:in combination with metformin particularly in overweight patients.in combination with a sulphonylurea only in patients who show intolerance to metformin or for whom metformin is contraindicated.",,2004-11-25T01:09:21Z,2005-04-18T00:09:21Z,https://www.ema.europa.eu/en/medicines/human/EPAR/venvia
human,Nyracta,"Diabetes Mellitus, Type 2",rosiglitazone,rosiglitazone,269,False,withdrawn,A10BG02,False,False,False,False,False,False,False,7/11/00,,SmithKline Beecham Plc,Drugs used in diabetes,,12/8/04,6.0,"Rosiglitazone is indicated as oral monotherapy in type 2 diabetes mellitus patients, particularly overweight patients, inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.Rosiglitazone is also indicated for oral combination treatment in type 2 diabetes mellitus patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea:- in combination with metformin particularly in overweight patients.­- in combination with a sulphonylurea only in patients who show intolerance to metformin or for whom metformin is contraindicated.",,2004-12-08T01:00:00Z,2005-04-18T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/nyracta
human,Cotronak,"Hepatitis C, Chronic",ribavirin,ribavirin,247,False,withdrawn,J05AB04,False,False,False,False,False,False,False,5/7/99,,Schering-Plough Europe,Antivirals for systemic use,,3/1/04,4.0,"Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.",,2004-03-01T01:00:00Z,2004-03-01T01:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/cotronak
human,Liprolog,Diabetes Mellitus,insulin lispro,insulin lispro,143,False,withdrawn,A10AB04,False,False,False,False,False,False,False,5/7/97,,Eli Lilly and Company Limited,"Insulins and analogues for injection, fast-acting , Drugs used in diabetes",,2/19/01,0.0,For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.,,2001-02-19T01:00:00Z,2001-08-01T00:00:00Z,https://www.ema.europa.eu/en/medicines/human/EPAR/liprolog
